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 EXECUTIVE SUMMARY 
Background and aims 
Although designed primarily to detect affected individuals, some newborn 
screening programmes inadvertently identify newborn infants who are carriers∗ 
of the inherited conditions for which screening is offered.  With the expansion 
of newborn blood spot screening for sickle cell disorders and cystic fibrosis 
(CF) in the UK, and other conditions bringing similar challenges in the USA, 
there is an urgent need to develop clear guidance as to how to respond. 
Depending on the condition for which screening is offered, options include 
employing tests that do not identify carrier status, if available; identifying 
acceptable ways of disclosing carrier status; identifying acceptable ways of not 
disclosing carrier status; or not screening. Currently, there are no screening 
tests available for sickle cell disorders that do not identify carrier status. For 
cystic fibrosis, the policy decision is between an extended period of testing, 
and a screening result that is available sooner for most newborns, but 
inadvertently identifies carrier babies. 
The aim of this systematic review is to assess the impact of communication 
about disclosing carrier status following newborn screening; and to collate the 
relevant evidence about parents’ and health professionals’ views.  
Methods 
We sought communication studies relating to the disclosure to parents of 
carrier results or false positive results following routine bloodspot screening. 
We searched: commercially available electronic databases, specialist registers 
online journals, online abstracts and conference abstracts. We also scanned 
the reference lists of included papers for reports that addressed 
communication about disclosing carrier status to parents following newborn 
screening for sickle cell disorders or cystic fibrosis.  
Two researchers independently scanned titles and abstracts for relevance 
using the pre-specified inclusion criteria. Full reports of selected citations were 
then located and screened again for relevance by two researchers 
independently. At each stage, results were compared and discrepancies 
resolved by discussion.  
Relevant reports were described according to the country in which the study 
was carried out, the study population, the setting of the study and the study 
design. Reports were also described in terms of their focus on specific health 
conditions (sickle cell disorders only, cystic fibrosis only, or sickle cell 
disorders and cystic fibrosis together). We also described reports in terms of 
the communication reported between health professionals and parents, which 
health professionals were involved, the timing of the communication, and 
whether raised IRT (immunoreactive trypsin: a screening test for cystic 
fibrosis in newborns) or carrier results were communicated. 
                                                
∗ Carriers of sickle cell disorders are often referred to as having or carrying sickle cell 
‘trait’. For consistency across the conditions, we have chosen to use the term ‘carrier’ 
rather than ‘trait’ throughout this report. 
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 Studies were reviewed in-depth if they: 
• addressed the impact of communication about disclosing carrier status 
using a soundly controlled trial or randomised controlled trial, or  
• described parents’ or practitioners’ views or experiences of disclosing 
carrier status following newborn screening. 
Studies of people’s views were appraised for:  
• the quality of the reporting of a study’s aims, context, rationale, methods 
and findings;  
• the sufficiency of the reported strategies employed to establish the 
reliability and validity of data collection tools and methods of analysis, and 
hence the validity of the findings; and  
• the appropriateness of the reported study methods for ensuring that 
findings about disclosing carrier status were rooted in parent’s and/ or 
health professionals’ own perspectives.  
The included studies were examined by two reviewers independently to seek 
authors’ findings in relation to the following questions: 
Are views reported on whether disclosing carrier status (for sickle cell disease 
or cystic fibrosis) identified as a result of newborn screening 
• provides lifetime health information for the child 
• informs reproductive planning for the parents 
• does not have psychosocial implications for the family 
• has no emotional impact on parents 
• has no emotional impact on other family members 
• has no effect on parental behaviour towards the child 
• does not alter relationships between parent and partner, or parents 
and other family members? 
Is disclosing raised IRT results or carrier status acceptable to parents? 
Is disclosing raised IRT or carrier status acceptable to health professionals? 
Are views reported on whether the outcomes above are independent of: 
• the timing and content of pre-test or post-test information (prior to or 
following the heel-prick test when first blood sample is taken) 
• the health professional providing the information 
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 • parental knowledge of conditions screened for (e.g. information 
received during antenatal period) 
• parental awareness of general risk of sickle cell disorders or cystic 
fibrosis (e.g. ethnic background, antenatal information, pre-test 
information) 
• parental awareness of specific risk for their child (e.g. family history, 
antenatal screening for same child, knowledge of own status) 
• method of disclosing test result (e.g. letter, offer of appointment, letter 
with telephone number for follow-up support, accompanying 
information) 
• follow-up support for families with carrier babies.  
Are views reported on whether the inability always to provide clear diagnosis 
for cystic fibrosis: 
• has psychosocial implications for the family 
• is acceptable to parents and health professionals? 
The reviewers compared their extracted findings and discrepancies were 
resolved by discussion. The findings from the studies were pooled under each 
research question. 
Findings 
We identified 24 relevant studies. There were nine intervention studies that 
addressed particular interventions to support communication. There were 16 
non-intervention studies: reviews, economic evaluation and needs 
assessment about disclosing carrier status to parents.  
Of the fifteen intervention studies, ten were from the USA; although most of 
the more recent evidence (three reports) were from England, Wales and 
Australia. Nine intervention studies were about cystic fibrosis and six were 
about sickle cell disorders or haemoglobinopathies more generally. 
Intervention study populations included parents (11), mothers (2) and couples 
(not necessarily parents yet) (2). Most intervention reports addressed 
communication at the time of results disclosure (11) or later (9). Two 
addressed antenatal communication, three at the time of the heel prick, and 
two at the time of a subsequent test. Interventions included information/ 
education only (4), advice/ counselling (6) or a combination (5). Interventions 
were fairly evenly split between community and primary care and secondary 
care (hospital or specialist clinic). Interventions were provided by a wide range 
of health professionals (health visitors, doctors and nurses (both specialists 
and non-specialists) and counsellors. Between them, the intervention studies 
addressed communication about the full range of possible test results. Six 
studies met the inclusion criteria for in-depth review: all were studies of 
parents’ views. 
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 In-depth review  
We found no controlled trials of interventions and are therefore unable to 
provide evidence about the impact of communication. 
None of the identified studies addressed the views of health professionals 
The included studies were mainly from the USA, although more recent 
evidence came from England and Wales. Five studies addressed universal 
screening for cystic fibrosis and one addressed selective1 screening for sickle 
cell disorders. Five were studies of parents and another was a study of 
mothers. The study of sickle cell disorders focused on sickle cell counselling; 
the studies of cystic fibrosis were evenly split between information and 
education interventions and genetic counselling. Most studies focused on 
communication in a specialist clinic although some focused on communication 
in the home or another health care unit or community site. Between them, 
studies addressed communication throughout the screening pathway, with 
different health providers involved at each stage in the pathway.  
Study designs precluded generating evidence about the impact of disclosure. 
Five of the six studies were of sufficient quality to rely on their findings about 
parents’ views. Parents of cystic fibrosis carriers favoured newborn screening 
and knowing the carrier status, and anticipated telling their child in due course. 
Cystic fibrosis carrier status led to problems with insurance companies with 
some families in the USA. A minority of parents used carrier status to inform 
reproductive planning, although when their child’s carrier result was withheld 
for four years following newborn screening, parents were angry at being 
denied the opportunity to do so. Discovering their own carrier status could also 
be an emotional event for parents. Few parents appeared to change their 
behaviour towards their carrier child. Discussing carrier status with the wider 
family was perceived as difficult, but necessary. 
Raised IRT test results began a roller coaster of emotion for parents; this 
could also be difficult for the wider family who were simultaneously trying to be 
supportive. For some parents, false positive results could be a continuing 
cause for concern. 
Parents would like some forewarning of possible results, but not to have ‘too 
much’ information. Parents favoured having familiar, non-specialists report test 
results to them; with these non-specialists being sufficiently briefed and not 
alarmist. The presence of cystic fibrosis specialists to discuss raised IRT 
results alarmed parents, as did being giving information about cystic fibrosis at 
that stage. 
There is little or no evidence about how outcomes are influenced by: parents’ 
previous knowledge of the screened conditions; the methods of 
communicating test results; or follow-up support 
There is no reliable evidence about the implications for parents of an unclear 
diagnosis for cystic fibrosis. 
                                                
1 Selective screening is screening which takes place on a targeted population selected 
using some other criteria, eg ethnicity 
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 Implications 
Policy 
The findings of this review provide some support for a policy decision to 
include DNA testing early in the screening protocol in order to reduce the 
numbers of parents experiencing excessive anxiety between hearing of a 
positive screening result (raised IRT test) and a confirmed result. However 
little is known about how to support non-specialists communicating with 
parents about carrier status or the need for further testing.  
There is no support for not disclosing newborn carrier status or raised IRT test 
results to parents. 
Parents prefer positive screening results or requests for repeat tests to be 
communicated by a familiar, non-specialist community/ primary care 
practitioner. Investment is needed in materials and training to support these 
health professionals to undertake well a task they may rarely, if ever, 
encounter. There is a particular need for interventions to support parents who 
wish to discuss screening results with their wider family. 
Parents, older children who are CF carriers and practitioners should be 
involved in developing these interventions.  
Practice 
Individual practitioners have a responsibility to forewarn parents about the 
possibility of positive screening results or requests for repeat tests and, when 
they occur, to discuss these with parents themselves rather than referring 
them to specialist services prematurely. 
Research 
With a dearth of published research findings about disclosing sickle cell carrier 
status, we recommend seeking grey literature through practitioner networks. 
We found no research addressing the issue of disclosing non-paternity 
through identification of carrier status in newborn screening. This should be 
addressed with primary research. 
Research is particularly needed about the implications for parents of an 
unclear diagnosis for cystic fibrosis and how to provide appropriate follow-up 
care. 
Some parents would like to be offered carrier testing for other children. As this 
contradicts current guidelines, we recommend research to explore the views 
of parents and children, and the possible implications. 
Parents and practitioners should be involved in this research. 
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 Aims 
The aim of this systematic review is to assess the impact of communication 
about carrier status following newborn screening; and to collate the relevant 
evidence about parents’ and health professionals’ views. 
The objectives of this review are to assemble the evidence to test the following 
hypotheses: 
A) Disclosing raised IRT results or carrier status for sickle cell disorders or 
cystic fibrosis (CF): 
• provides lifetime health information for the child 
• informs reproductive planning for the parents 
• does not have psychosocial implications for the family 
• has no emotional impact on parents 
• has no emotional impact on other family members 
• has no effect on parental behaviour towards the child 
• does not alter relationships between parent and partner, or parents 
and other family members 
• is acceptable to parents 
• is acceptable to health professionals. 
 
B) The outcomes above are independent of: 
• the timing and content of pre-test or post-test information (prior to or 
following the initial heel-prick test, when the first blood sample is taken) 
• the health professional providing the information 
• parental knowledge of conditions screened for (e.g. information 
received during antenatal period) 
• parental awareness of general risk of sickle cell disorders or cystic 
fibrosis (e.g. ethnic background, antenatal information, pre-test 
information) 
• parental awareness of specific risk for their child (e.g. family history, 
antenatal screening for same child, knowledge of own status) 
• method of disclosing test result (e.g. letter, offer of appointment, letter 
with telephone number for follow-up support, accompanying 
information) 
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 • follow-up support for families with carrier babies.  
 
C) The inability always to provide clear diagnosis for cystic fibrosis: 
• has psychosocial implications for the family 
• is acceptable to parents  
• is acceptable to health professionals. 
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 1. BACKGROUND 
 
Outline of chapter 
 
This chapter sets the scope for the systematic review and will therefore be of 
interest to all readers of this report. 
 
Key messages 
 
• Some newborn screening programmes inadvertently identify genetic 
carriers of conditions being screened 
 
• Depending on the condition being screened, the solution may be to 
employ tests that do not identify carrier status, if available; identify 
acceptable ways of disclosing carrier status; identify acceptable ways 
of not disclosing carrier status; or stop screening 
 
• There are currently no screening tests available for sickle cell disorders 
that do not identify carrier status 
 
• For cystic fibrosis, the policy decision is between an extended period of 
testing using a method which does not identify carriers, and a 
screening result that is available sooner for most newborns, but 
inadvertently identifies carrier newborns 
 
• Existing related reviews have focused extensively on the evidence for 
the effects on children’s health of screening for sickle cell disorders 
and cystic fibrosis  
 
• There are a number of non-experimental studies exploring parents’ 
experiences of newborn screening and the possible psychosocial 
implications of disclosing results 
 
• The scope of this review encompasses both evidence of the 
effectiveness of communication about disclosing results, and non-
experimental studies exploring the views of parents and health 
professionals 
 
Newborn screening blood spot programmes aim to identify babies who do not 
have any symptoms but are at risk of developing serious health conditions. 
Criteria for quality programmes include screening tests and subsequent 
diagnostic procedures, treatment and intervention that are clinically, socially, 
and ethically acceptable to health professionals and the public (National 
Screening Committee, 2002). This is particularly important for population 
based screening programmes, even more than selective screening 
programmes which focus on individuals already known to be at high risk.  
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 The potential quality of some screening programmes may be compromised 
because the tests inadvertently identify babies who are unaffected, but who 
carry one copy of a gene for a condition. These babies are referred to as 
'carriers'2. The health problems of carriers are distinct from the health 
problems of affected babies, in that the information is of no immediate benefit 
to their health or treatment. However, there are known short-term as well as 
long-term problems, such as misdiagnosis if the presumptive screening result 
is incorrect, inadvertent exposure of non-paternity, social stigma for the 
individual and family, and adverse psychological effects for the individual and 
family (Laird et al., 1996 Marteau et al., 1992);. Depending on the condition for 
which screening is offered, the solution may be to: 
• employ tests that do not identify carrier status, if available; 
• identify acceptable ways of disclosing carrier status; or  
• identify acceptable ways of not disclosing carrier status. 
 
Two screening programmes that raise this dilemma screen for sickle cell 
disorders3 and cystic fibrosis. While screening programmes for these 
conditions may benefit affected babies and their families, they also pose 
important social, ethical, psychological, and medical challenges at a societal 
level.  
Biochemical tests for sickle cell disease carried out on blood spots collected 
by heel-prick test inadvertently identify carrier babies. Depending on the ethnic 
composition of the population screened, between 17 and 100 carrier babies 
will be identified for each affected child detected. Carrier status may have 
implications for the baby's future reproductive choices, but it is unclear 
whether families do indeed make use of this information when making future 
decisions. While babies who are carriers for sickle cell disease do not need 
medical attention, the implication is that, once their carrier status is revealed, it 
also reveals the carrier status of the parents. Rarely, this may expose a case 
of ‘non-paternity’, revealing that the child's putative father is not the biological 
father (Macintyre and Sooman, 1991). There are currently no screening tests 
available for sickle cell disorders that do not identify carrier status. There is 
therefore a clear need to understand the perceptions of parents and health 
professionals, and the impact of methods for disclosing, or not disclosing, 
carrier status. 
Cystic fibrosis screening can raise different dilemmas. Babies who are carriers 
of cystic fibrosis, and their parents, may face the challenge of a series of tests 
spread over time with possibly uncertain results and no subsequent benefit. 
                                                
2 Carrier status for sickle cell disorders may also be described as ‘sickle cell trait’. 
3 Sickle cell disorders affect the haemoglobin and fall into a broader group of 
conditions known as haemoglobinopathies. A number of studies identified in this 
review refer to screening for haemoglobinopathies and discuss the communication of 
carriers of haemoglobinopathies. Whilst newborns are only screened for sickle cell 
disorders, most pregnant women are screened for other haemoglobinopathies, notably 
thalassaemias. We have tried to be accurate in our use of terms for these overlapping, 
but different, groups of conditions. 
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 Blood spots are tested biochemically for immunoreactive trypsin (IRT): if the 
IRT is raised, some, but not all, of these babies are at higher risk of 
developing cystic fibrosis. The test is repeated on a repeat sample taken some 
weeks later in order to reduce the number of false positive screening results. If 
the IRT remains raised with the second test, the baby’s sweat is tested for its 
saltiness (sweat test) in order to confirm or refute a diagnosis of cystic fibrosis. 
A sweat test is always conducted in hospital. Results at all stages may be 
equivocal and parents may have to cope with an extended period of 
uncertainty about their baby’s health. 
DNA-based testing for cystic fibrosis was originally introduced to reduce the 
number of babies undergoing relatively late diagnostic testing with the sweat 
test. DNA tests identify common mutations that quickly identify affected 
babies. Unfortunately, this can raise problems for some babies and their 
families, as the DNA test will also identify babies that are either carriers or 
unaffected, but for whom a diagnosis of cystic fibrosis cannot be reliably 
excluded. This is because cystic fibrosis can arise from many different 
mutations but only the more common ones are identified in routine screening. 
Consequently, the choice of tests (biochemical, genetic and physiological) for 
screening and subsequent diagnosis, the order in which the tests are 
conducted, and the mutations that are tested for in the babies’ DNA all 
influence the length of the testing period and the degree of uncertainty of the 
results. For cystic fibrosis the policy decision is between an extended period of 
testing that may leave some families with equivocal results, and a screening 
result that is available sooner for most babies, but inadvertently identifies 
babies who are carriers. Evaluating the options may include direct 
comparisons of the different screening options, including the views of parents 
and health professionals, or comparing methods of disclosure and non-
disclosure of carrier status in the context of DNA testing. 
Newborn screening also identifies babies who are carriers for other conditions, 
although we shall not include them in the scope of this review for various 
reasons that are explained here. Carrier testing and disease detection of 
maple syrup urine disease has been reported for a particular high-risk group, 
but not sufficiently so for comprehensive population screening to be employed 
(Love-Gregory et al., 2001). Detection of Medium Chain Acyl CoA 
Dehydrogenase Deficiency (MCADD) may involve DNA analysis for a 
common gene mutation, but the number of carriers detected is very small. 
Also, because there are many secondary biochemical markers available, 
reliance on mutation testing can be reserved for when there is doubt about 
diagnosis, rather than being employed for population screening (Carpenter et 
al., 2001). 
Existing related reviews have focused extensively on the evidence for the 
effectiveness of screening for sickle cell disorders and cystic fibrosis. This 
evidence has been systematically retrieved and assembled in two Cochrane 
reviews and in three reviews commissioned by the UK Health Technology 
Assessment (HTA) programme. The Cochrane review on sickle cell disease 
(Lees et al., 2000) found no trials on the reduction of adverse short- and long-
term outcomes of neonatal screening compared with symptomatic diagnosis. 
In the Cochrane review on cystic fibrosis (Merelle et al., 2000) only two trials 
were identified, one in the UK and one in Wisconsin, USA. Neither of the trials 
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 examined the impact or acceptability, of disclosing carrier status.  
Two of the HTA-commissioned reviews focus primarily on the cost-
effectiveness of screening rather than the effects of information disclosure 
(Davies et al., 2000); (Zeuner et al., 1999). The HTA review on cystic fibrosis 
(Murray et al., 1999) predominantly covers antenatal screening, but found little 
information on parents’ knowledge of neonatal screening, or the psychological 
implications, other than anxiety measures, of disclosing results, or effects on 
reproductive planning of parents of carrier babies. Two studies were identified 
examining effects on the parent-child relationship following the disclosure of 
results, but these only included affected babies. 
There are a number of non-experimental studies exploring parents’ 
experiences of newborn screening and the possible psychosocial implications 
of disclosing results. In relation to the Wisconsin trial mentioned above is the 
Wisconsin Study (Ciske et al., 2001), a questionnaire study involving parents 
of screened children, focusing on the communication of carrier status of cystic 
fibrosis. This showed that genetic counselling increased knowledge of the 
condition as well as decreased the emotional implications of guilt and 
confusion. A review of reviews identified other studies that focus heavily on 
the emotional implications of genetic testing, but a notable gap about 
communicating sickle cell carrier status following newborn screening (Stewart 
and Oliver, 2003). Anxiety is often used as a measure of emotional impact on 
parents of the disclosure of results following newborn screening (Hall et al., 
2000); (Shaw et al., 1999), usually in the context of the timeline inherent in the 
communication of results.  
With regard to sickle cell disorders, some studies concentrate on the social 
impact of being affected or of being a sickle cell carrier (Antley et al., 1973); 
(Wooldridge and Murray, 1988), or on the knowledge base of parents with 
carrier infants (Hampton et al., 1974). Another psychosocial implication is the 
issue of false paternity (non-paternity) and is relevant for both conditions. One 
study clearly illustrates a central dilemma inherent in disclosing carrier status 
(Lucassen and Parker, 2001) which is the issue of confidentiality. The debate 
emphasises the question of to whom the information belongs: the child, the 
mother, the couple or the health service. This may raise social and ethical 
issues involving other members of the family, in some cases leading to 
cascade testing (in which relatives of carriers are tested for mutations) 
(Holloway and Brook, 1994; Turner, 1993).  
The scope of this review encompasses both evidence of the effectiveness of 
communication about disclosing results, and evidence of the views of parents 
and health professionals from non-experimental studies. 
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 2. METHODS 
 
Outline of Chapter 
This chapter describes the methods used in the review. It was carried out in 
two broad stages: 
 
• an initial mapping exercise to describe the range of studies available 
and relevant to disclosing carrier status to parents following newborn 
screening 
• an in-depth review focusing on a sub-set of these studies, chosen to 
gather evidence of people’s views and the effects of communication 
 
The mapping exercise was carried out in three stages: (i) defining the scope 
of the mapping and developing inclusion and exclusion criteria; (ii) identifying 
studies falling within that scope; and (iii) describing these studies. 
 
The in-depth review was carried also carried out in three stages: (i) application 
of inclusion and exclusion criteria; (ii) quality assessment and data extraction; 
and (iii) synthesising the findings of studies of people’s views. 
 
Readers who are primarily interested in the findings of the review may skip 
this chapter, but it may be of interest to: 
 
• any readers who want to check how the review was conducted; and  
• researchers and information specialists or others interested in 
carrying out systematic reviews, especially those who want to read 
about how different types of research can be included in a systematic 
review, in particular research that is ‘qualitative’ in nature. 
 
2.1 Inclusion and exclusion criteria for mapping exercise 
This review focussed on studies about the communication of carrier results to 
parents following newborn screening for sickle cell disorders or cystic fibrosis. 
 
Four criteria were developed to ensure that only relevant reports were 
reviewed: 
 
Criteria 1: health intervention 
Reports were excluded from the review if they did not describe newborn 
screening. 
Criteria 2: health condition 
Reports were excluded from the review if they considered neither sickle cell 
disorders or cystic fibrosis. 
Criteria 3: results 
Reports were excluded from the review if they did not consider at least one of 
the following results: carrier, trait, heterozygote, false-positive.  
Criteria 4: communication intervention 
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 Reports were excluded from the review if they did not consider communication 
with parents. 
2.2 Identification of relevant studies 
 
The aim of the literature search was to locate a wide variety of research about 
disclosing carrier results to parents following newborn screening for sickle cell 
disorders and cystic fibrosis. Specifically, the search focused on four areas: 1) 
the health intervention of newborn screening and blood spot test; 2) screening 
and diagnostic tests and results relevant to sickle cell disorders and cystic 
fibrosis; 3) disclosure of results, and 4) possible outcomes and factors that 
may have an impact following screening and disclosure of results (see 
Appendix 2.2). 
A variety of sources of published and unpublished literature were searched to 
locate relevant reports. These included:  
• commercially available electronic databases (Medline, PsychInfo, Cinahl, 
Cochrane Library, Embase, Social Sciences Citation Index, African Trials 
Registry),  
• specialist registers (MIDIRS, African Health Anthology, LILACS, Cochrane 
Cystic Fibrosis and Genetics Disorders Group Specialist Register, 
Cochrane Consumers and Communications Group Specialist Register),  
• online journals (Anthropology & Medicine), and 
• online abstracts (for the European Meeting on Psychosocial Aspects of 
Genetics, May 2002), and conference abstracts (25th European Cystic 
Fibrosis Conference, Genoa, Italy, June, 2002). 
For Medline and Embase highly sensitive search strategies were developed 
using combinations of controlled vocabulary and free-text terms restricted to 
title, abstract, or keyword fields. A wide range of terms were used combining 
terms for: 
• newborn screening and blood spot test (e.g. infant, newborn, neonatal, 
baby, perinatal, blood specimen, heel prick, Guthrie card, etc.)  
• screening and diagnostic tests and results (e.g. sickle cell, cystic fibrosis, 
carrier, immunoreactive trypsin, sweat test, etc.),  
• the disclosure of results (e.g. communication, confidentiality, duty to warn, 
information, parents, etc.) 
• possible outcomes and factors of screening and disclosure (e.g. stress, 
psychosocial impact, false paternity, genetic counselling, ethics, etc.). 
Search strategies for PsychInfo, and the Social Sciences Citation Index were 
adapted by replacing controlled medical terms not supported by these 
databases with free-text terms. Terms combined covered those relating to 
newborn screening and blood spot test, screening and diagnostic tests and 
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 results, and the disclosure of results. 
All other database and registers were searched using simple terms (e.g. sickle 
cell, cystic fibrosis) or simplified combinations of terms used in the Medline 
search strategy (see Appendix A for the full details used in these search 
strategies). 
All citations identified by the literature searches were downloaded or entered 
into a Reference Manager database. They were scanned for relevance using 
the pre-specified inclusion criteria for this review (see above, 2.1). 
The reference lists of all included studies were scanned for relevant citations, 
and experts in the field were also contacted to ask for relevant literature. 
 
2.3 Classification of relevant studies 
 
Full reports were obtained and first classified according to a standardised 
keywording system developed by the EPPI-Centre (Peersman et al., 1997). 
This classifies reports in terms of the type of study (e.g. survey, outcome 
evaluation, intervention), the country in which the study was carried out, the 
study population, and the setting of the study.  
In order to gain a more detailed description of reports specifically addressing 
the aim of this review, an additional standardised set of keywords was 
developed. This keywording system (details of which can be obtained from the 
EPPI-Centre on request) classified reports in terms of health condition and 
communication. 
Health condition 
Reports were described in terms of their focus on specific health conditions, 
whether this was on sickle cell disorders only, cystic fibrosis only, or broader 
screening programmes that included both sickle cell disorders and cystic 
fibrosis. 
Communication 
Reports were described in terms of whether any form of communication was 
reported between health professionals and parents, which health 
professionals were involved, the timing of the communication, and whether 
raised IRT or carrier results were communicated. 
 
2.4 Selection of studies for in-depth review 
 
Studies were reviewed in-depth if they did one of the following: 
• Evaluated the effects of communication intervention with a randomised 
controlled trial (RCT); 
• Evaluated the effects of communication intervention, reporting pre-
intervention and post-intervention data for each group, reporting findings 
for each outcome measure indicated in the aims of the study; and 
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on socio-demographic and outcome variables (soundly controlled trial); 
• Evaluated the processes of communication interventions that are also 
evaluated for their outcomes as in (a) or (b) above (associated process 
evaluations); 
• Described parents’ or practitioners’ views or experiences of disclosing 
carrier status following newborn screening (views studies); 
 
2.4 Appraisal of studies in in-depth review 
 
Twelve questions cover three main quality issues. Of these, five relate to the 
quality of the reporting of a study’s aims, context, rationale, methods and 
findings: 
• Were the aims and objectives clearly reported? 
• Was there an adequate description of the context in which the research 
was carried out (including a rationale for why the study was carried out)? 
• Was there an adequate description of the sample used and the methods 
for how the sample was identified and recruited? 
• Was there an adequate description of the methods used to collect data? 
• Was there adequate description of the methods used to analyse data? 
 
A further four questions relate to the sufficiency of the reported strategies 
employed to establish the reliability and validity of data collection tools and 
methods of analysis, and hence the validity of the findings.  
 
Was there ‘some attempt’; a ‘good attempt’; or ‘no attempt’ to establish the 
following:   
 
• the reliability of data collection tools; 
• the validity of data collection tools; 
• the reliability of the data analysis methods; and 
• the validity of data analysis methods. 
 
The final three questions related to the assessment of the appropriateness of 
the reported study methods for ensuring that findings were rooted in parents’ 
own perspectives. In relation to this, reviewers were asked to judge studies 
according to whether they:  
 
• used appropriate data collection methods for helping parents to express 
their views; 
• used appropriate methods for ensuring the data analysis was grounded in 
the views of parents  
• actively involved parents in the design and conduct of the study. 
 
Examples of markers that reviewers used for judging appropriateness 
included: the use of open-ended questions or response categories informed 
by pilot work; avoiding the use of pre-defined coding strategies for analysing 
the data from interviews or focus groups; and involving parents in project 
steering or advisory groups.  
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 2.5 Extraction and synthesis of findings from studies 
reviewed in-depth 
 
The studies reviewed in depth were examined by two reviewers independently 
to seek authors’ findings in relation to the following pre-determined questions 
to match hypotheses emanating from the background literature: 
Are views reported on whether disclosing carrier status (for sickle cell disease 
or cystic fibrosis) identified as a result of newborn screening: 
• provides lifetime health information for the child; 
• informs reproductive planning for the parents; 
• does not have psychosocial implications for the family; 
• has no emotional impact on parents; 
• has no emotional impact on other family members; 
• has no effect on parental behaviour towards the child; 
• does not alter relationships between parent and partner, or parents and 
other family members; 
 
Are views reported on whether the outcomes above are independent of: 
• the timing and content of pre-test or post-test information (prior to or 
following the heel-prick test when first blood sample is taken); 
• the health professional providing the information; 
• parental knowledge of conditions screened for (e.g. information received 
during antenatal period); 
• parental awareness of general risk of sickle cell disorders or cystic fibrosis 
(e.g. ethnic background, antenatal information, pre-test information); 
• parental awareness of specific risk for their child (e.g. family history, 
antenatal screening for same child, knowledge of own status); 
• method of disclosing test result (e.g. letter, offer of appointment, letter with 
telephone number for follow-up support, accompanying information), and 
• follow-up support for families with carrier babies? 
 
Are views reported on whether the inability to always provide clear diagnosis 
for cystic fibrosis: 
• has psychosocial implications for the family; 
• is acceptable to parents, and  
• is acceptable to health professionals? 
 
The reviewers compared their extracted findings. Discrepancies were resolved 
by discussion. Taking each question in turn, the agreed findings from each 
study addressing a question were summarised and reported in a narrative. 
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 3. RESULTS: DESCRIBING THE LITERATURE 
 
Outline of Chapter 
 
This chapter presents: 
• a description of the flow of studies through different stages of the 
review, including brief details of the studies eventually excluded from 
the in-depth review 
• a detailed description of the views studies that met our inclusion 
criteria for the in-depth review 
 
A searchable database of all the studies identified for this review is available 
on-line at http://eppi.ioe.ac.uk/ 
 
This chapter will be of interest to: 
• researchers or commissioners of research wishing to set an agenda 
for future inquiry, or considering conducting a similar mapping exercise 
• practitioners, policy specialists and parents interested in the types 
of research conducted 
 
Key findings 
• Twenty-four separate studies were identified for our mapping exercise.  
 
• There were 16 intervention and 9 non-intervention studies 
 
• Ten intervention studies were from the USA; most of the more recent 
evidence (three reports) were from England and Wales  
 
• Nine intervention studies were about cystic fibrosis and six were about 
sickle cell disorders or haemoglobinopathies more generally 
 
• Intervention study populations included parents (11), mothers (2) and 
couples, not necessarily parents (2) 
 
• Most intervention reports addressed communication at the time of 
results disclosure (11) or later (9). Two addressed antenatal 
communication, three at the time of the heel prick, and two at the time 
of a subsequent test 
 
• Interventions included information/ education only (4), advice/ 
counselling (6) or a combination (5) 
 
• Interventions were fairly evenly split between community and primary 
care and secondary care (hospital or specialist clinic) 
 
• Interventions were provided by a wide range of health professionals 
(health visitors, doctors and nurses (both specialists and non-
specialists) and counsellors). 
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 • Between them, the intervention studies addressed communication 
about the full range of possible test results 
 
• . There were no controlled trials of communication interventions. 
 
• Six studies met the inclusion criteria for in-depth review: all were 
studies of parents’ views 
 
3.1 Identification of relevant studies 
The search strategy for this review yielded 1803 citations in total (see Fig 1). 
Of these 1717 were excluded on the basis of their title or abstract. Eighty-six 
papers were identified for inclusion and full reports sought. Unfortunately five 
reports were unavailable, and these papers therefore had to be excluded on 
this basis. These five reports could not be traced by the British Library. In two 
cases the authors were contacted, but no replies were received. 
The 81 collected reports were screened again and a further 57 papers 
excluded at this stage. Twenty-four full reports were therefore eligible for 
inclusion in the first ‘mapping stage’ of this review. These 24 reports are 
described in more detail below. 
 
Source of identified reports (see Table 1) 
Thirteen of the twenty-four reports were identified through commercially 
available databases. These included Medline (6 reports), the Cochrane Library 
(5 reports), and Embase (2 reports). An additional 6 reports were found 
through specialist registers, including MIDIRS (3 reports), and the Cochrane 
Cystic Fibrosis and Genetic Disorders Group Register (3 reports). One report 
was identified through personal contact with other researchers in the UK and 
the remaining 3 reports were identified by scanning the reference lists of all 
collected reports. 
 
Table 1: Source of identified reports (N=25) 
Commercial bibliographic databases 13 
Specialist bibliographic registers 6 
Personal contact 2 
Reference lists 3 
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 stage screening:   
Figure 1: Literature 
Two 
Papers identified from 
searches 
N = 1803
Abstracts 
and titles 
screened 
Papers 
excluded  
N = 1717 
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Systematic map  
(see section 3.2) 
 
24 reports  
describing 24 studies 
Full 
document 
screened 
N = 81
Potential includes 
N = 86
Papers 
excluded  
N = 57 
Papers not 
obtained  
N = 5 
Papers 
excluded: 
Not views 
or trials 
N = 18
Applied in 
depth 
criteria  
N = 24
In-depth review  
(See section 4) 
 
Views studies         Trials 
N = 6 N = 0
 3.2 Characteristics of studies 
 
The twenty-four studies included in the mapping stage of the review covered a 
range of study types; two were guidelines (see table 2).  
 
Table 2: Types of studies included in the map (N=25)  
Study type    N 
Systematic review  1 
Non-systematic review  3 
Survey  1 
Needs assessment  1 
Economic evaluation 1 
Guidelines 2 
Total non-intervention studies      9 
Intervention description 3 
Process evaluation  1 
Randomised controlled trial 2 
Case control study 3 
Other outcome evaluations 5 
Other qualitative study 1 
Total intervention studies  15 
 
3.2.1 Non-intervention studies 
Nine non-intervention studies were identified. Two of these were not reports of 
primary research, but were published guidelines.  
We identified one systematic review and three other reviews. The systematic 
review focussed on the effectiveness and cost of newborn screening for cystic 
fibrosis, as well as other inborn errors of metabolism (Pollitt et al., 1997). The 
other three reviews focussed on the potential implementation (Wildhagen and 
Ten Kate, 1998), potential outcomes (Laird et al., 1996), and effectiveness 
(Murray et al., 1999), of newborn screening for cystic fibrosis.  
Two further reviews commissioned by the NHS Health Technology 
Assessment programme were excluded because they did not focus on 
communication of carrier results following newborn screening (Lees et al., 
2002); (Zeuner et al., 1999). However, they referred to other studies that did 
fall within our scope of interest. 
We identified one survey, which focussed on policy and practice in state 
newborn screening programmes for cystic fibrosis in the USA (Farrell et al., 
2001). The economic evaluation focused on the cost of population screening 
for cystic fibrosis (Wildhagen et al., 1998). We identified one relevant needs 
assessment of haemoglobinopathy educational provision for midwives and 
senior student midwives (Dyson SM et al., 1996). 
None of the non-intervention studies were designed to provide evidence about 
the impact of disclosure to parents of newborn carrier status following 
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3.2.2 Intervention studies 
 
Fifteen of the identified studies were intervention studies. Nine reports were 
about cystic fibrosis and five about sickle cell disorders. An additional study 
focussed on haemoglobinopathies more broadly. We considered: the study 
designs applied, where the studies were conducted; the populations studied; 
the screening protocols in use; the timing and type of the communication; 
where this occurred and with whom; and the type of test results 
communicated. 
Study design  
The intervention studies included two randomised controlled trials (RCTs) of 
screening interventions with communication studies nested in them. Other 
intervention studies included one case-control study, and five other 
evaluations addressing impact (mainly post-test only). In addition, we 
identified one process evaluation and an additional qualitative study.  
Where they were conducted 
Of the nine studies about cystic fibrosis, six studies were from the USA 
(Baroni et al., 1997); (Ciske et al., 2001); (Mischler et al., 1988); (Tluczek et 
al., 1991); (Tluczek et al., 1992); (Wheeler et al., 2001),  two from England 
(McLaughlin et al., 1999); (Moran and Quirk, 2002), and one from Wales 
(Parsons et al., 2003).  
Of the five studies focussing on sickle cell disorders, four were from the USA 
(Grossman et al., 1985); (Hurst, 1989); (Whitten et al., 1981); (Yang et al., 
2000), and one from the UK (Anionwu, 1983). The study which focussed on 
unspecified haemoglobinopathies was based in the UK (Rao et al., 1996). 
Screening protocols 
Twelve of the 15 intervention studies described universal newborn screening: 
nine for cystic fibrosis and three for sickle cell disorders. The other three 
studies described selective screening for sickle cell disorders.  
Study population 
Eleven of the fifteen studies described communication with ‘parents’ and two 
with ‘mothers’. Two studies focussed on communication with ‘couples’ 
antenatally. 
 
Timing and type of communication  
The timing of communication with parents about newborn screening described 
in the 15 intervention studies spanned a timeline from the antenatal period, 
through to discussions after the results (see Table 3). Several studies 
described communication at more than one point. 
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 Table 3: Timing of communication in intervention studies (N=15)   
Timing Frequency 
antenatal 2 
neonatal/pre-screening 1 
at time of heel-prick test 3 
at time of subsequent test 2 
result disclosure 11 
post-result disclosure 9 
NB Some studies describe communication with parents at more than one time. 
Routine antenatal appointments or antenatal classes provide one of the 
earliest opportunities for health professionals to communicate with parents 
about possible outcomes of newborn blood spot screening. Two intervention 
studies describe communication with couples in the antenatal period. One 
study focussed on communication in the neonatal period, after the birth but 
prior to the heel prick test. Three studies looked at communication at the time 
of the heel-prick test, and two at the time of a subsequent test. The majority of 
studies described communication with parents at the time of disclosing results 
(11 studies), or afterwards, for example during counselling (19 studies). 
Two types of interventions were identified: counselling (or giving advice) and 
information giving (or education). Six of the 15 intervention studies described 
counselling interventions only, four described education interventions only, 
while five described interventions that included elements of both counselling 
and education (see Table 4). 
 
Table 4: Type of intervention described (N = 15) 
Intervention type N 
Counselling and information 5 
Counselling only 6 
Information only 4 
 
Five of the 15 intervention studies included both information giving and 
counselling. Information was given antenatally (Yang et al., 2000), or following 
result disclosure (Mischler et al., 1988); (Yang et al., 1990). Information was 
also given in relation to requesting a second blood sample when a raised IRT 
was disclosed and parents were counselled on possible outcomes at the same 
time (Moran and Quirk, 2002). Three of the six identified studies were merely 
descriptions of interventions: one study described provision of information for 
parents about the need for further tests for cystic fibrosis, and follow up 
counselling following disclosure of carrier results (McLaughlin et al., 1999). A 
similar study described provision of information for parents of babies found to 
be sickle cell carriers, including giving a card recording the exact result, and 
follow-up counselling after this disclosure (Rao et al., 1996).  
Six of the 15 intervention studies were counselling interventions only; 
counselling occurred at the time of the heel-prick test and at results disclosure 
(Ciske et al., 2001), at the neonatal/pre-screening stage and at the time of the 
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 heel-prick (Grossman et al., 1985), at the time of results disclosure and as 
follow-up (Hurst, 1989), at the time of the subsequent test and as follow-up 
(Wheeler et al., 2001), and as follow-up after result disclosure (Whitten et al., 
1981). Another study described provision of counselling for couples thought to 
be at risk of having a child with a sickle cell disorder following receipt of their 
own, or their child’s, test results, including communication about the 
implications of the test results (Anionwu, 1983). 
The four intervention studies that were information interventions only 
described information being given at the time of the heel-prick test (Tluczek et 
al., 1992), and information given in the form of screening test results (Baroni et 
al., 1997); (Parsons et al., 2003); (Tluczek et al., 1991).  
Intervention sites 
 
All 15 intervention studies described the place where the communication took 
place. This varied widely (see Table 5).  
 
Table 5: The sites of the communication intervention (N=15)  
Intervention site N 
Home  7 
Community site  1 
Primary care  3 
Hospital  3 
Specialist clinic  8 
Educational institution  1 
Secondary education  1 
NB Some studies describe communication with parents at more than one site. 
 
In seven of the 15 intervention studies, communication took place in the home. 
One study described communication at a community site, and three described 
communication taking place in a primary care setting. Three  other studies 
described communication taking place in a hospital. Eight studies described 
communication taking place in specialist clinics. These specialist clinics varied 
from a specialist cystic fibrosis clinic (Tluczek et al., 1992), a sickle cell 
counselling centre (Anionwu, 1983); a mobile health unit (Whitten et al., 1981) 
and an academic centre (Wheeler et al., 2001). Whilst one study described 
communication in an educational institution, another specified communication 
as part of secondary education.   
 
Six studies reported communication in more than one intervention site. For 
example parents may have been told screening test results through a phone 
call received at home followed by genetic counselling provided at a specialist 
clinic. 
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 Intervention provider (health professional) 
Twelve of the 15 intervention reports specified which health professional was 
involved in the communication process (see Table 6) .The remaining three 
reports did not specify who was involved in communication with parents. 
 
Three intervention studies involved health visitors communicating with parents 
(Moran and Quirk, 2002); (Parsons et al., 2003); (Rao et al., 1996). This 
communication included requesting a second blood sample (Moran and Quirk, 
2002), and informing parents of the need for further tests, such as a sweat test 
(Parsons et al., 2003) and informing parents of the test result (Rao et al., 
1996).   
Six interventions described doctors communication with parents, either in their 
capacity as family doctors communicating test results to parents (Ciske et al., 
2001); (Parsons et al., 2003); (Tluczek et al., 1991), or as specialists in 
relation to specific conditions. For example paediatricians and respiratory 
physicians were involved in communicating results of sweat tests for the 
diagnosis of cystic fibrosis (Hurst, 1989); (Parsons et al., 2003), as were 
physicians attached to a specific cystic fibrosis centre (Tluczek et al., 1991), 
whereas a consultant haematologist was involved in communication about 
sickle cell carrier results (Tluczek et al., 1991).  
Follow-up support is usually available for parents in the form of counselling 
about the genetic implications of their child’s test results. Different nurses are 
described as providing this counselling in six intervention studies. These 
nurses included: nurse practitioners (Ciske et al., 2001), clinic nurses (Hurst, 
1989), specialist nurses (Rao et al., 1996), postgraduate level nurses 
(Mischler et al., 1988), cystic fibrosis nurse specialists (McLaughlin et al., 
1999), and cystic fibrosis nurses (Moran and Quirk, 2002). Three studies 
included sickle cell counsellors (Anionwu, 1983); (Hurst, 1989); (Whitten et al., 
1981). Other health professionals involved as intervention providers included 
genetic counsellors (Ciske et al., 2001); (Mischler et al., 1998); (Wheeler et al., 
2001); , and a non-physician counsellor (Grossman et al., 1985). 
Table 6: Person communicating  
Person communicating N 
Health visitor 3 
Doctor (GP, physician, respiratory physician, paediatrician, 
consultant haematologist) 
6 
Nurse (nurse practitioner, clinic nurse, specialist nurse, 
postgraduate level nurse, cystic fibrosis nurse specialist, 
cystic fibrosis nurse) 
6 
Sickle cell counsellor 3 
Genetic counsellor 3 
Non-physician counsellor – not specified 1 
NB Some studies describe more than one information provider.  
Communication of screening test results 
 
Since this was a criterion for inclusion in the review, all 15 intervention studies 
reported the communication of newborn screening results to parents (see 
Table 7). There are 10 interventions (within 9 intervention studies) that relate 
Disclosing to parents newborn carrier status following routine blood spot 
screening 25 
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to the communication of sickle cell carrier results.  
 
Five interventions described the communication of CF carrier status to 
parents. These used varying language to describe the results including:  ‘CF 
carrier’ (Parsons et al., 2003), ‘CF heterozygote’ (Ciske et al., 2001), ‘CF 
heterozygote carrier status’ (Baroni et al., 1997), and ‘carrying one CF 
mutation’ (McLaughlin et al., 1999); (Wheeler et al., 2001).  
 
Five studies described communicating ‘false-positive’ cystic fibrosis results to 
parents (Ciske et al., 2001); (Mischler et al., 1988); (Moran and Quirk, 2002); 
(Tluczek et al., 1991); (Tluczek et al., 1992). This term was used to refer to 
three different circumstances:  
• In the early reports of the Wisconsin screening programme babies 
with one raised IRT were then given sweat tests. Those babies with 
negative sweat tests are described as ‘false-positive’ results (Tluczek 
et al., 1991, Tluczek et al 1992 and Mischler et al 1988).  
• The Ciske et al (2001) paper describes a later stage in the Wisconsin 
screening programme referring to ‘false-positive results’ to describe 
those babies identified as having a raised IRT and one mutation, who 
then have a negative sweat test.  
• Moran and Quirk (2002) interviewed parents of babies who had had 
an initial raised IRT results, were told about the initial ‘positive’ result 
and the need for a second blood sample, but were subsequently 
given the all clear.  
In each case parents are approached and warned of the possibility that their 
baby has CF, and subsequent tests show that this is not the case.  
 
Six of the 15 intervention studies described the communication of sickle cell 
carrier results to parents (Anionwu, 1983); (Grossman et al., 1985); (Hurst, 
1989); (Rao et al., 1996); (Whitten et al., 1981); (Yang et al., 2000). One of 
these (Rao et al., 1996) described the communication of ‘haemoglobinopathy 
trait’ rather than sickle cell carriers. This broader terms implies that this paper 
may have considered thalassaemia carriers as well as sickle cell carriers.  
 
 
Table 7: The different newborn screening results communicated 
Newborn screening test results N 
Cystic fibrosis carrier  
(cystic fibrosis mutation / cystic fibrosis heterozygote) 
5 
Cystic fibrosis ‘false positive’  
(initial raised IRT, ‘normal second IRT)  
5 
Sickle cell carrier  
(including ‘haemoglobinopathy’ carrier) 
6 
NB Some studies described communication of more than one type of result. 
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 4. RESULTS: IN-DEPTH REVIEW  
 
Outline of Chapter 
 
This chapter presents a synthesis of the findings of the six studies we 
identified that examined the views of parents about disclosing carrier status 
following newborn screening. It describes findings from included studies as 
they relate to each of the research questions. 
 
All types of readers are likely to be interested in this chapter 
Key messages 
 
• No included studies addressed the views of health professionals 
 
• The six included studies were mainly from the USA, although more 
recent evidence came from England and Wales  
 
• Five studies addressed universal screening for cystic fibrosis and one 
addressed ‘selective’ screening for sickle cell disorders 
 
• Five were studies of parents and another was a study of mothers 
 
• The study of sickle cell disorders focused on genetic counselling; the 
studies of cystic fibrosis were evenly split between information and 
education interventions and genetic counselling  
 
• Most studies focused on communication in a specialist clinic although 
some focused on communication in the home or another health care 
unit or community site 
 
• Between them, studies addressed communication throughout the 
screening pathway, with different health providers involved at each 
stage in the pathway 
 
• Five studies were of sufficient quality to rely on their findings about 
parents’ views 
 
• Parents of cystic fibrosis carriers reported that they favoured newborn 
screening and knowing the carrier status, and anticipated telling their 
child in due course 
 
• Some parents reported that false positive results could be a continuing 
cause for concern 
 
• Some parents in the US studies reported that cystic fibrosis carrier 
status led to problems with insurance companies  
 
• A minority of parents reported using carrier status to inform 
reproductive planning, although when results were withheld parents 
were angry at being denied this opportunity 
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• Raised IRT test results were reported as starting a roller coaster of 
emotion for parents; this could also be difficult for the wider family who 
were simultaneously trying to be supportive 
 
• Discovering their own carrier status could also be an emotional event 
for parents 
 
• Few parents appeared to change their behaviour towards their carrier 
child 
 
• Discussing carrier status with the wider family was perceived as 
difficult, but necessary 
 
• Parents would like some forewarning of possible results, but not to 
have ‘too much’ information 
 
• Parents favoured having familiar, non-specialists report test results to 
them, with these non-specialists being sufficiently briefed and not 
alarmist 
 
• The presence of cystic fibrosis specialists to discuss raised IRT results 
alarmed parents, as did being giving information about cystic fibrosis at 
that stage 
 
• There is little or no evidence about how outcomes are influenced by: 
parents’ previous knowledge of the screened conditions; the methods 
of communicating test results; or follow-up support 
 
• There is no reliable evidence about the implications for parents of an 
unclear diagnosis for cystic fibrosis 
 
4.1 Characteristics of the studies reviewed in-depth 
 
The studies reviewed in-depth were described in terms of where they were 
conducted; the screening protocols in use; the populations included in the 
study; the communication interventions employed, at what point in the 
screening pathway and by whom; and the study design applied. 
Country of intervention 
Most of these studies were conducted in the USA (Ciske et al., 2001; Tluczek 
et al., 1991; Wheeler et al., 2001; Whitten et al., 1981)  although the most 
recent studies were conducted elsewhere; in England (Moran and Quirk, 
2002), and in Wales (Parsons et al., 2003).  
Screening programmes  
Of the six studies selected for in-depth review, five addressed screening for all 
newborns (universal newborn screening) for cystic fibrosis (Ciske et al., 2001); 
(Moran and Quirk, 2002); (Parsons et al., 2003); (Tluczek et al., 1991); 
(Wheeler et al., 2001) and two addressed newborn screening for those 
perceived as being at higher risk of sickle cell disorders (selective screening) 
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 (Moran and Quirk, 2002); (Whitten et al., 1981).  
The details of screening tests and the timing of communication studied were 
different in each report. Tluczek et al. (1991) addressed the communication of 
a single raised IRT test and the reporting of a negative sweat test. Moran et al. 
(2002) addressed the request for a second blood sample for a repeat IRT test 
and DNA analysis. They did not report on disclosing carrier status following 
subsequent DNA analysis. Parsons (2003) addressed the reporting of DNA 
analysis early in the screening pathway and the request for a sweat test. Ciske 
et al (2001) studied the acceptability of disclosing carrier status following a 
sweat test. Wheeler et al (2001) addressed disclosing carrier status following 
a single IRT test and DNA analysis.  
Study populations 
Five studies included parents (Moran and Quirk, 2002; Parsons et al., 2003; 
Tluczek et al., 1991; Wheeler et al., 2001; Whitten et al., 1981) and another 
addressed only mothers (Parsons et al., 2003). Only two studies reported the 
ethnic groups of the participants (Tluczek et al., 1991; Wheeler et al., 2001) 
and none of the studies distinguished between ethnic groups in the provision 
of the intervention or involvement in the research. 
Communication interventions 
The study of sickle cell disorders (Whitten et al., 1981) focused on genetic 
counselling; the studies of cystic fibrosis were split between information and 
education interventions (Moran and Quirk, 2002); (Parsons et al., 2003); 
(Tluczek et al., 1991) and genetic counselling (Ciske et al., 2001); (Moran and 
Quirk, 2002); (Wheeler et al., 2001). 
Site of communication intervention 
Most studies focused on communication in a specialist clinic (Ciske et al., 
2001); (Parsons et al., 2003); (Tluczek et al., 1991); (Wheeler et al., 2001); 
(Whitten et al., 1981) although some focused on communication in the home 
(Parsons et al., 2003); (Tluczek et al., 1991) or a community site (Whitten et 
al., 1981). 
Timing of communication 
In terms of the screening pathway, the communication under investigation 
occurred at the time of the heel-prick test (Ciske et al., 2001), at the time of 
subsequent tests (Moran and Quirk, 2002); (Wheeler et al., 2001), at the time 
of disclosing test results to parents (Ciske et al., 2001); (Moran and Quirk, 
2002); (Parsons et al., 2003); (Tluczek et al., 1991) and at the time of follow-
up (Wheeler et al., 2001); (Whitten et al., 1981). 
Health intervention provider  
Following the initial heel–prick test, communication was between: parents and 
a health visitor and cystic fibrosis nurse reporting raised IRT levels and 
explaining the need for further tests (Moran and Quirk, 2002); parents and 
physicians for a sweat test (Tluczek et al., 1991); parents and a genetic 
counsellor, nurse practitioner and physician who explained false positive 
results of IRT testing in the light of a negative sweat test (Ciske et al., 2001); 
parents and a sickle cell counsellor reporting sickle cell carrier results (Whitten 
et al., 1981); or parents and genetic counsellors following disclosure of cystic 
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 fibrosis carrier status (Wheeler et al., 2001). In some circumstances, parents 
communicated with a series of health professionals: with a health visitor or GP 
to inform them about sweat testing; with a paediatrician, specialist cystic 
fibrosis nurse and health visitor to arrange the date for the sweat test; and with 
a paediatrician for receiving the results of the sweat test on the same day 
(Parsons et al., 2003). 
Study design 
Intervention studies included a qualitative study of parents’ views (Moran and 
Quirk, 2002), a case control study (Parsons et al., 2003) and studies 
conducted to address the effects of communication. These latter outcome 
evaluations were a survey of counselling performance (Whitten et al., 1981) 
and surveys of parents following a communication intervention (Ciske et al., 
2001); (Tluczek et al., 1991); (Wheeler et al., 2001), one of which was 
embedded in an RCT (Tluczek et al., 1991). 
 
4.2 Quality of the studies reviewed in-depth 
4.2.1 Studies of impact of screening communication 
Four studies were presented by authors as evaluations of the outcomes of 
communication about newborn screening (Ciske et al., 2001); (Moran and 
Quirk, 2002); (Tluczek et al., 1991); (Whitten et al., 1981). However, their 
designs presented serious shortcomings as outcome evaluations. 
Two outcome evaluations which used a single group pre-test post-test design 
(Whitten et al, 1981) or a post test only design (Moran and Quirk, 2002) were 
not judged by the reviewers to be rigorous assessments of the impact of 
counselling (Whitten et al, 1981) or the impact of false positive results on 
psychosocial measures (Moran and Quirk 2002). However, both studies were 
considered appropriate for gathering parents’ views. 
Tluczek et al. (1991) aimed to report the psychological impact of false-positive 
results when screening for cystic fibrosis. However, their randomised 
controlled trial was useful in addressing the effects of newborn screening 
rather than the effects of communication of screening results. Their 
comparison of responses to raised IRT and subsequent negative sweat test 
(false positive results) with responses to raised IRT test results reported after 
a delay of four years was not a useful comparison for considering 
communication policy options.  
Ciske et al. (2001) aimed to assess the effectiveness of communication 
between health care providers (physicians, nurses, genetic counsellors) and 
parents of children identified as heterozygote carriers for cystic fibrosis in the 
routine Wisconsin Newborn Screening Program, USA, that was implemented 
using IRT for screening and sweat testing for diagnosis. However, without a 
control group, evidence of effectiveness is doubtful. 
4.2.2 Studies of people’s views 
All the studies reporting people’s views which we reviewed in depth were 
quality assessed, based on information reported in the publication. 
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 Study methods 
All studies reported their aims clearly and all but one described clearly the 
context of the study either by linking it to an existing body of empirical and/or 
theoretical research or by explaining why the study was done at that time, in 
those contexts and with those people or institutions.  
Five studies provided adequate descriptions of the study sample and of how 
the sample was identified and recruited.  
Fewer studies reported detailed methods: five adequately described the 
methods used in the study to collect data; five provided adequate description 
of the methods of data analysis; only three were judged replicable from the 
descriptions of the intervention, and methods for data collection and analysis. 
Two studies reported how they sought participants’ informed consent (Ciske et 
al., 2001; Moran et al., 2002). Two studies reported involving parents in 
piloting research instruments (Moran and Quirk, 2002; Tluczek et al., 1991). 
Strategies for establishing reliability and validity 
Two studies reported making some attempt to establish the reliability and 
validity of data collection methods and tools, and methods of analysis. Moran 
et al (2002) and Tluzcek et al (1991) piloted their interview schedule with 
parents and made several changes to procedures in light of this. Moran et al 
(2002) also calculated the inter-rater reliability of their analysis, whilst the 
Tluczek et al. (1991) study included a group of experienced grounded theory 
researchers to analyse data from interview transcripts. Data analysis was 
done both individually and as a group, being careful to remain focused on the 
parents' perceptions (Tluczek et al., 1991). 
Appropriateness of methods for exploring parents’ views 
Five studies clearly used appropriate data collection methods for helping 
parents to express their views (Ciske et al., 2001); (Moran and Quirk, 2002); 
(Parsons et al., 2003); (Tluczek et al., 1991); (Whitten et al., 1981); and four of 
these also reported appropriate methods for ensuring that the data analysis 
was grounded in the views of parents (Moran and Quirk, 2002); (Parsons et 
al., 2003); (Tluczek et al., 1991); (Whitten et al., 1981). 
 
Wheeler et al (2001) assessed the communication process solely in terms of 
parents’ decisions about cascade testing.  
Overall quality of studies (see Table 8) 
Three studies met seven or more of the ten quality criteria (Moran and Quirk, 
2002; Tluczek et al., 1991; Tluczek et al., 1992; Whitten et al., 1981) with 
methods fully reported, and steps taken to ensure that they collected and 
analysed  parents’ views appropriately. In addition, Tluczek et al (1991)  
involved parents in the design of the research instruments. 
Ciske et al. (2001) and Parsons et al. (2003) were less comprehensive in 
reporting their methods. Although they reported details for data collection, 
including methods for helping parents express their views, their reporting of 
data analysis was less detailed.  
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 Wheeler et al. (2001) met only three of the quality criteria. They did not report 
methods of data collection and therefore to the extent to which they present 
the views of study participants is unclear. For this reason, the findings have 
not been included in the synthesis of parents’ views. 
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 Table 8: Overall quality of studies 
 Study 
Quality criteria (Ciske et al., 
2001) 
(Moran and 
Quirk, 2002) 
(Parsons et al., 
2003) 
(Tluczek et al., 
1991) 
(Wheeler et 
al., 2001) 
(Whitten et 
al., 1981) 
The aims of the study are clearly reported 9 9 9 9 9 9 
The context of the study is adequately 
described (in terms of a link to the 
relevant literature and/ or …) 
9 9 9 9 9  
Adequate description of the sample used 
in the study and how the sample was 
identified and recruited 
9 9 9 9  9 
Methods used in the study to collect data 
are adequately described 
9 9 9 9  9 
Adequate description of the methods of 
data analysis 
 9  9 9 9 
Study replicable from this report  9  9  9 
Authors avoid selective reporting bias 
(e.g. do they report on all variables they 
aimed to study as specified in their 
aims/research questions) 
9 9 9 9  9 
Used appropriate data collection methods 
for helping parents to express their views 
9 9 9 9  9 
Used appropriate methods for ensuring 
the data analysis was grounded in the 
views of parents 
 9 9 9  9 
Actively involved parents in the design 
and conduct of the study 
     9 
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 4.3 Synthesis of health professional’s views 
None of these studies addressed the views of health professionals on 
communicating raised immunoreactive trypsin (IRT) results or carrier status for 
cystic fibrosis (CF) or sickle cell disorders. 
4.4 Synthesis of parents’ views about disclosing 
newborn sickle cell carrier status 
The only relevant study we could find was a study of counselling about sickle 
cell carrier results that was not restricted to newborn screening (Whitten et al. 
1981). Counsellees were adults who were sickle cell carriers or were parents 
of a child who was a sickle cell carrier. Of 192 counsellees, 153 were women, 
62 were married, 97 were under 30, 34 had no children, 110 had between 1 
and 3 children and 36 had more than 3; In 79 instances the counsellee had 
sickle cell trait, in 80 the child did, and in 33 both the counsellee and their child 
were carriers. Of the total, 140 had 12 or more years education, 47 had less than 
12, making this population better educated than average. Although participants’ 
knowledge was significantly higher if they had finished high school, there was no 
investigation as to whether there was any association between education and 
attitudes towards disclosing carrier status. 
4.4.1 Does disclosing newborn sickle cell carrier status provide lifetime 
health information for the child? 
 
Whitten et al. (1981) in their evaluation of sickle cell counselling speculated 
that the effects that being a carrier may have or is believed to have on health 
status or life span is a major cause of anxiety or concern. They reported 
parents anticipating passing on the information to their child:  
’I don't feel bad about it since I know more about it and I will explain it to her 
when she gets older. When she gets married she will decide‘ (Whitten et al., 
1981), p813. 
’I feel terrible, because the chances are that she (the daughter) could run into 
somebody with the trait (a carrier) and I would have to tell her not to have any 
children‘ (Whitten et al., 1981), p813.  
Whitten et al. (1981) speculated that a major cause of parental anxiety or is 
the effects being a sickle cell carrier may have on marriage and reproduction.  
4.4.2 Does disclosing newborn sickle carrier status provide information 
for reproductive planning for the parents? 
We could find nothing in the Whitten et al. (1981) study that shed light on this 
question. 
4.4.3 Does disclosing newborn sickle carrier status have psychosocial 
implications for parents? 
Whitten et al. (1981) found that at the beginning of their counselling session, 
29% of adults (carriers and parents of carriers) expressed no feelings about 
the diagnosis, 36% expressed positive or acceptance feelings, and 35% 
expressed feelings of anxiety. A comparison of feelings expressed before and 
after counselling showed a decrease from 35% to 17% in those who 
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 expressed anxiety (a 53% decrease). The percentage of people who 
expressed positive or acceptance feelings more than doubled, increasing from 
36% before the counselling to 74% after the counselling session. Only 6.3% 
(4) of the 63 adults who had positive or acceptance feelings at the beginning 
expressed anxiety after the counselling session was over. 
4.4.4 Does disclosing newborn sickle carrier status alter parental 
behaviour towards the child? 
Whitten et al. (1981) did not address this question. 
4.4.5 Does disclosing newborn sickle carrier status have implications for 
other family members? 
Whitten et al. (1981) did not address this question. 
4.4.6 Is newborn screening for sickle cell disorders acceptable to 
parents of newborns who are identified as carriers? 
Whitten et al. (1981) did not address this question. 
4.4.7 Are outcomes of disclosing newborn sickle carrier status 
influenced by the timing and content of pre-test and post-test 
information? 
When a sickle cell carrier was identified, many commented that achieving a 
better understanding of the distinctions between having a sickle cell disorder 
and being a carrier helped relieve anxiety (Whitten et al., 1981). 
’I don't feel bad about it since I know more about it and I will explain it to her 
when she gets older. When she gets married she will decide‘ (Whitten et al., 
1981), p813. 
4.4.8 Are outcomes of disclosing newborn sickle carrier status 
influenced by which health professional provides parents with 
information? 
No evidence was found relating to sickle cell screening. 
4.4.9 Are outcomes of disclosing newborn sickle carrier status 
influenced by parents’ previous knowledge of the screened conditions? 
Only one study considered the significance of parents’ previous knowledge of 
the condition, and none of them considered parents’ awareness of either 
population risks, or their specific risks, of having the screened conditions.   
Whitten et al. (1981) quoted one mother saying: 
’It makes you worry. I have a cousin who has sickle cell and she is in and out 
of the hospital‘ (Whitten et al., 1981), p813. 
4.4.10 Are outcomes of disclosing newborn sickle carrier status 
influenced by the method of communicating screening test result? 
No evidence was found relating to sickle cell screening. 
4.4.11 Are outcomes of disclosing newborn sickle carrier status 
influenced by follow-up support?  
No evidence was found relating to sickle cell screening. 
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 4.5 Synthesis of parents’ views about disclosing raised 
IRT results 
Parents’ views about disclosing raised IRT results were addressed in four 
studies (Ciske et al 2001; Moran and Quirk, 2002; Parsons et al., 2003; 
Tluczek et al., 1991). The studies on 21 parents in England (Moran and Quirk, 
2002) and 11 parents in Wales (Parsons et al., 2003) presented no socio-
demographic data. Of the 168 families eligible for the Moran and Quirk (2002) 
study, 36 were not contactable. Tluczek et al. (1991) included parents of 104 
infants with false positive IRT test results. Of these, 78% were white; 64% 
were married; and 40% of mothers and 43% of fathers had education beyond 
high school. Parents with higher educations had significantly greater 
knowledge about newborn screening. There was no investigation of variation 
in parents’ views. 
 
Ciske et al. (2001) included parents of 138 families. Their educational 
background was diverse, but again, better educated than a comparable 
population of Wisconsin young adults. Ciske et al. (2001) did not investigate 
parents’ knowledge about raised IRT (only carrier status), or how education 
may relate to differences in their views. 
4.5.1 Does disclosing raised IRT test results provide lifetime health 
information for the child? 
Such information could be a cause for a lifetime of concern. Tluczek et al. 
(1991) found that, despite how carefully the contacts were made, parents who 
were told much later of their child’s raised IRT test seemed to discount or not 
hear reassurances. These parents continued to believe the worst and 
described painful images of their child's future. 
4.5.2 Does disclosing raised IRT test results provide information for 
reproductive planning for the parents? 
Tluczek et al. (1991) found that most families of newborn carriers for CF (69%) 
did not change their reproductive plans based upon their experience with 
neonatal screening. However, 8% reported that they had changed their minds 
about having additional children, and 22% were uncertain at the time of the 
sweat test. Neither education nor the method of communicating test results 
was significantly related to these changes in plans. However, when raised IRT 
results were withheld for four years as part of the blinding of the screening 
intervention in the Wisconsin Trial, parents expressed anger about the 
delayed disclosure. They felt misled and robbed of the opportunity to make life 
decisions regarding reproduction. 
4.5.3 Does disclosing raised IRT test results have psychosocial 
implications for parents? 
Between them studies revealed psychosocial implications for parents at each 
stage of the CF screening pathway. 
Moran et al. (2002) reported a roller coaster of emotions from the time when 
parents are told the results of an initial raised IRT test until they are told their 
child does not have CF. The main feelings in response to this result were 
'worry/ concern/ nervous/ anxious' and a number reported being 'devastated/ 
distraught/ hysterical' and 'upset'. For parents with prior concerns about their 
newborn’s health, this news 'felt like another burden'. One third reported their 
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 mood as 'unhappy/ depressed'.  
For 57%, the waiting time between the second heel-prick test and IRT test 
result was unsatisfactory, three quarters of whom had to wait 7 days. Two 
reported having waited approximately 3 weeks for the result and two of those 
waiting over 10 days commented that this had been due to a bank holiday 
falling in the waiting period. Two thirds stated that reducing the waiting period 
would have made this time less stressful. 
At the time of the second heel-prick test, parents still reported feeling 'nervous/ 
anxious/ worried/ concerned' and some commented that they were in 'shock/ 
felt unreal' and also felt 'guilty'. However, nearly half the group stated that they 
also felt 'glad it was being done' and two parents said they 'wanted an answer'. 
One third described their mood as being 'low/ depressed' at this time. 
Waiting for the test results of the second heel-prick test was the time when 
parents experienced the widest range of feelings. Most parents (64%) 
identified with more than one feeling, and several reported four or five. 
Specifically, nearly one third stated they had 'thought about future with CF', 
either having convinced themselves their child had CF or preparing 
themselves for how they would cope emotionally and practically. Just under 
one third commented that they 'tried to carry on as normal' although they 
indicated that this was not easy. All parents stated additional feelings. When 
asked to describe their mood at this time, just under half stated they were ‘low/ 
down/ depressed’ and one third said they were ‘nervous/ anxious/ 
apprehensive’. Three respondents reported hyper-vigilance, looking for signs 
and symptoms of CF and noticing CF in the media, and three were 'upset/ 
crying'. 
When individual participants' responses were examined, 'depressed/ low/ 
unhappy' and 'nervous/ anxious/ concerned' were the most consistently 
reported mood states across the time periods. 'Angry' and 'changeable mood' 
were also reported at two time periods by individuals. Several described 
moods at each stage and in most cases where one mood remained 
consistent, other moods varied. This suggests that whilst there were some 
feelings and moods that were consistent, it seems the majority of parents 
experience a range and mix of emotions throughout. 
All but two parents reported being informed of the final all clear result by the 
CF nurse. This was usually communicated by telephone. For three quarters, 
the second result convinced them that their child was not affected by CF. 
However, several parents made additional comments that they continued to 
have some anxiety about their child's health (e.g. chest problems, breathing, 
other illnesses) which led them to question the reason for the initial raised IRT 
test result. For 86%, a routine follow-up from the CF nurse after the all clear 
result was not seen to be necessary and several commented that they just 
wanted to get on with things. 
A narrower range of feelings was reported when the final all clear result was 
given; 70% reported relief and other commonly reported feelings as 'happy/ 
over the moon/ elated / fantastic'. In addition to these feelings, two noted 
negative feelings: 'frustrated at what [we] had been through' and 'thinking of 
other families who receive CF diagnosis'. One reported 'no feelings/ numb' 
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 which was consistent with feelings during the waiting period. Relief and 
happiness were the overriding emotions. 
In the first few weeks after receiving the 'all clear', relief was common. Three 
parents also reported that they felt angry. For two this was related to the way 
that they had been told about the initial raised IRT result by the health visitor. 
Looking back, 43% of parents reported 'memories of a difficult time'. Three 
parents reported being 'upset/ sad looking back', two reported still being angry 
about the experience and three expressed 'feelings for other families going 
through it or families of sick children'. One parent reported that they 'rarely 
think of it – doesn't upset me'. 
These findings were supported by a study in Wales. When parents were 
asked about how they felt at the time, (following the raised IRT screening test 
and prior to diagnostic sweat test) they talked about ’feeling afraid‘, ’being 
worried‘, the news being ’like a dark cloud‘, ’being in a state‘, and a feeling of 
’shock‘ (Parsons et al., 2003). 
Ciske et al. (2001) also found that a majority of responders indicated that the 
waiting was the worst part of the experience, although only 23% suggested 
decreasing the waiting time to have a sweat test. 
Tluczek et al. 1991 mounted a randomised controlled trial of screening for 
cystic fibrosis. In the intervention arm of the trial, they reported raised IRT test 
results and offered sweat tests for the newborns. In the comparison arm they 
took the blood spot, but did not report the results of the IRT test for four years, 
allowing time for individuals with cystic fibrosis to be diagnosed through 
symptoms. This provided an opportunity to study how parents reacted when 
the sweat tests of their newborn indicated that cystic fibrosis was not 
suspected: false positive results. Parents responded with an array of 
emotions. The news of the abnormal screening test produced anxiety that was 
both emotionally and physically disruptive. Parents expressed emotions 
suggesting grief for an anticipated loss. In many cases, the activities of daily 
living were significantly altered and parents experienced somatic symptoms. 
Parents who were given timely information about the raised IRT result, and 
had to wait 3 days for the sweat test, were thankful that, if their child had a 
problem, the problem was found early (86%). However, they were also 
concerned or anxious (98%); depressed/ sad (77%); shocked (76%); 
disbelieving (52%); confused (61%); or angry (48%). Few had no reaction or 
were calm (4%). When parents were faced with ambiguous, incomplete, or 
uncertain information, they filled their information gap in any way they could. 
Information seeking had the consequence of parents accessing inaccurate 
sources and increased anxiety for parents. In contrast, four parents seemed 
calm if not indifferent in their response. These parents described having 
concerns initially, but were reassured by their child's good health and/or 
statements by their paediatrician that CF was not likely to be diagnosed. 
After four years, raised IRT test results were disclosed to parents in the other 
arm of the trial and they were offered a sweat test for their child. These 
parents were concerned or anxious (67%), depressed/ sad (67%), shocked 
(17%), disbelieving (56%), confused (72%), angry (67%) or had no reaction or 
were calm (17%). Parents of babies where the disclosure of the initial raised 
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 IRT test result was delayed by four years were split into two categories: those 
with emotionally charged responses (14/18 parents) or those with calm, 
indifferent responses to the news of an abnormal IRT test that was performed 
during their child's neonatal period. Parents expressed anger about the 
delayed disclosure. They felt misled and robbed of the opportunity to make life 
decisions regarding reproduction. Parents in this group seemed to discount or 
not hear reassurances. These parents continued to believe the worst and 
described painful images of their child's future. 
4.5.4 Does disclosing raised IRT test results alter parental behaviour 
towards the child? 
Moran et al (2002) found that most parents described themselves as 
'sometimes', 'rarely' or 'never' anxious about their child's health. Nine 
described themselves as 'quite protective', three 'not protective' and two 'over 
protective' (one due to on-going health difficulties). Only one reported 
continuing anxieties about the raised result, which was due to her child 
suffering from repeated chest infections: 
’I actually felt half of me didn't want him - rejecting him - one minute I had a 
perfect baby then next minute this. Not that I didn't love him. Just wanted it all 
over with and to get on’ (Moran and Quirk, 2002), p22. 
4.5.5 Does disclosing raised IRT test results have implications for other 
family members? 
Moran et al. (2002) investigated the psychosocial effects of false-positive 
results on parents and families. Whilst a number of feelings reported for 
partners were the same as or similar to those expressed by the participants. 
Some participants said they were not aware of how their partners and families 
were feeling. In some cases it seemed this was associated with fathers’ 
coping strategies; being optimistic, putting on a brave face or trying to support 
the mother. Alternatively, with fathers at work there may have been limited 
opportunity for mothers to gauge their partner's coping.  
Where partners and families are involved and aware, the repeat screening 
procedure appears to be a difficult time in terms of the emotions they are 
experiencing. It was reported that families frequently tried to be supportive and 
reassuring but they themselves were also experiencing a range of emotions at 
the different stages. From the news of the initial raised result until the final all 
clear result, 'upset', 'anxious/ concerned/ worried' were frequently reported 
feelings for the partner and family. When the all clear result was given, 'relief/ 
weight lifted' and categories such as 'happy/overjoyed' were most frequent 
and similar to the participants’ responses. 
4.5.6 Is newborn screening acceptable to parents who were told of raised 
IRT results? 
Moran et al. (2002) found that parents’ comments generally indicated that they 
viewed it as a difficult time that is in the past. Several commented that they 
viewed the CF screening as necessary despite a false positive result. All 
parents stated that they were in favour of routine newborn screening for CF. 
Most reported being 'OK' with the initial heel-prick test and there was a sense 
that it was viewed as routine and necessary. 
Parsons et al. (2003) also reported that all the families who had their baby 
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 identified as a carrier were in favour of newborn screening even though they 
had experienced uncertainty at the time of being told that another test was 
required. 
In contrast, Tluczek et al. (1991) reported in detail the anger expressed by 
parents when, within the context of informed consent for participating in an 
RCT, raised IRT test results were kept from parents for four years (see 
above).  
4.5.7 Are outcomes of disclosing raised IRT results influenced by the 
timing and content of pre-test and post-test information? 
In a CF programme employing an IRT test (Ciske et al., 2001), DNA test and 
sweat test, when asked how the newborn screening process should be 
improved, 55% of parents replied that they wished they had had more 
background information about the implications of the screening result earlier, 
before bringing their child for a sweat test. Although only 23% of parents 
suggested decreasing the waiting time to have a sweat test, the majority of 
parents indicated that the waiting was the worst part of the experience. The 
authors concluded that educational materials should be made available earlier 
and disseminated throughout community clinics. Ciske et al. (2001) concluded 
that educational programmes must be in place for both lay public and 
healthcare providers regarding the implications of newborn screening 
programmes.  
Moran et al. (2002) reported parents’ views about initial raised IRT results and 
requests for a second heel-prick test. For 86%, enough information was 
available about the repeat test and responses suggested that the information 
provided included basic written information about CF and information about 
the possibility of false positives. One parent commented that the nurse asked 
questions about symptoms but was not in a position to provide any answers or 
reassurance; this seemed to increase anxiety. At this point some parents also 
commented that they did not want too much information and responses 
indicated that the amount of information given varied according to individual 
need. For 43% of parents, enough information was available about initial 
raised IRT results. Although over half stated that they did think enough 
information was available to them at this time, there was a range of views 
about what they would have liked. Four would have liked more information 
about the condition and/or procedure at this stage (possibly leaflets) and one 
wanted more reassurance from the health visitor. However, 43% did not want 
too much information; some commenting that more would have frightened 
them. When asked to identify things that were helpful about the way the raised 
IRT result was given, several parents thought it had been helpful that they had 
been advised about false positives at this point. Where this had not happened, 
two would have preferred this. One said that the shock of receiving the initial 
raised IRT result could be reduced by informing parents at the time of the 
heel-prick test of the possibility of false positives and the feedback procedure 
for results. 
4.5.8 Are outcomes of disclosing raised IRT results influenced by which 
health professional provides parents with information? 
All three studies that addressed parents’ views of the significance of the 
choice of health professional providing information about newborn screening 
for CF focused on community services: health visitors (Moran and Quirk, 
Disclosing to parents newborn carrier status following routine blood spot 
screening 40 
 2002); (Parsons et al., 2003) and specialist CF nurses working with them 
(Parsons et al., 2003), and community physicians (Ciske et al., 2001). 
Over 75% parents stated that the health visitor informed them of the initial 
raised IRT result and 71% reported the health visitor was the best person to 
inform them (Moran and Quirk, 2002). One reason given was that this person 
was more likely to be familiar with the family. Of those who reported that this 
was not the best person to give the result, the majority commented that the 
health visitor did not have sufficient information about the illness and 
screening procedure and false positives and would have preferred her to be 
more informed on these subjects. In addition to the content of information 
given, responses revealed that the way in which the news was delivered was 
important. Several noted how the health visitor’s manner contributed to the 
negative impact of this event: being alarmist, expressing urgency and the 
need for the partner's presence (Moran and Quirk, 2002). 
Policy in Wales is for health visitors to be accompanied by a specialist CF 
nurse to request a second blood sample. In the study by Parsons et al. (2003), 
on four occasions two health professionals had called on the family to 
communicate results: the health visitor and a specialist CF nurse. For these 
families, this visit by a specialist to talk about CF just confirmed their worst 
fears. 
In Wisconsin, USA, 14% of parents experiencing positive screening results felt 
that community physicians (paediatricians and family physicians) needed 
better education about the implications of a positive newborn screen for CF to 
be able to explain possible consequences more effectively to parents (Ciske et 
al., 2001). The authors concluded that educational programmes must be in 
place for both lay public and health care providers regarding the implications 
of newborn screening programmes. 
4.5.9 Are outcomes of disclosing raised IRT results influenced by 
parents’ previous knowledge of the screened conditions? 
None of the studies considered the significance of parents’ previous 
knowledge of the cystic fibrosis, and none of them considered parents’ 
awareness of either population risks, or their specific risks, of having the 
screened conditions.   
4.5.10 Are outcomes of disclosing raised IRT results influenced by the 
method of communicating screening test result? 
In the Welsh study (Parsons et al., 2003) families had been given details 
about CF whether they had been visited by their health visitor, or the specialist 
nurse. Both these approaches raised unnecessary anxiety. In some cases 
they had been left with a CF Trust leaflet. The majority of families recalled the 
negative language that had been used:  
’they just showed no sympathy, no warning, they just blurted it out‘ (Parsons et 
al., 2003), p10. 
A CF nurse leaving a leaflet from the CF Trust for parents to read caused 
parents to believe their child would have CF. 
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 4.5.11 Are outcomes of disclosing raised IRT results influenced by 
follow-up support?  
Follow-up support can be provided in the form of counselling and carrier 
testing of parents, but few studies addressed this and none related to sickle 
cell screening. For 86% of parents experiencing false positive raised IRT test 
results in Moran et al’s study (2002), a routine follow up from the CF nurse 
after the all clear result was not seen to be necessary and several commented 
that they just wanted to get on with things again.  
4.5.12 What are the implications of an unclear diagnosis for cystic 
fibrosis? 
No studies addressed potential psychological implications arising from unclear 
diagnosis for cystic fibrosis.  
 
 
4.6 Synthesis of parents’ views about disclosing 
newborn carrier status for cystic fibrosis 
Two studies addressed parents’ views about disclosing newborn carrier status 
for cystic fibrosis. Each employed a different screening pathway. Parsons et 
al. (2003) addressed the reporting of DNA analysis early in the screening 
pathway and the request for a sweat test. Ciske et al. (2001) studied the 
acceptability of disclosing carrier status following a sweat test.  
Parsons et al. (2003) conducted their study in Wales with 11 parents of 
carriers identified through newborn screening, but presented no socio-
demographic data. Ciske et al. (2001) included parents of 138 families who 
had diverse educational backgrounds but were generally better educated than 
a comparable population of Wisconsin young adults. They found correct 
responses to questions assessing knowledge about carrier status were 
statistically independent of educational background. They did not investigate 
any variation in parents’ views. 
4.6.1 Does disclosing CF carrier status provide lifetime health 
information for the child? 
Two studies reported parents’ views of this information in terms of their child’s 
lifetime health.  
Parsons et al. (2003) reported that all the families whose babies were 
identified as a carrier for CF reported being in favour of newborn screening. 
Typically, they reported favouring knowing the carrier status, and having the 
information available when the children start their own families. Parents were 
all aware that at some point in the future they would have to pass the 
information on. There was also a feeling that at some point the young person 
would have to make his or her own decisions. 
Ciske et al. (2001) reported some problems with insurance companies in the 
USA. Of 26 cases in which the insurance company was notified of the child's 
status, 5 reported having some difficulties as a consequence. . Two other 
families who did not inform their insurance company about the child's carrier 
status also reported difficulties. The remaining 108 families did not inform their 
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 insurance company and did not experience problems. 
4.6.2 Does disclosing CF carrier status provide information for 
reproductive planning for the parents? 
Ciske et al. (2001) found that antenatal testing for CF was used by 14% of 
parents in a subsequent pregnancy. In one family, antenatal testing was used 
in two subsequent pregnancies.  
4.6.3 Does disclosing CF carrier status have psychosocial implications 
for parents? 
 
Newborn carrier status: Ciske et al. (2001) found the majority of parents felt 
better informed and were glad to be aware of their child's CF carrier status. 
The majority were not confused or experiencing feelings of guilt.  
Parental carrier status: The inevitable consequence of a baby being 
identified as a CF carrier is that at least one parent is also a carrier. Parsons 
et al. (2003) explored parents’ attitudes in relation to their own carrier status. 
In this study 6 of the fathers and 4 of the mothers were carriers. After 
discovering their own carrier status (as a consequence of newborn screening 
and subsequent cascade testing) individuals felt 'a bit apprehensive', 'gutted', 
or 'uncomfortable' or 'guilty' about passing on the gene.  
Six months later, all carriers were philosophical about their status. The 
parents' accounts focused on three main issues. Firstly, they all made 
reference to the fact that their baby was ’perfectly healthy‘. In two families, 
adult carriers had made the connection between their own continued health 
and the fact that their baby was going to be the same. Second, the way the 
families talked about their baby's carrier status indicated that it caused them 
very little concern. They talked about their children as being ’just a carrier‘ or 
’only a carrier‘. Third, they were all aware that at some point in the future they 
would have to pass the information on. 
There were two parents however who felt some guilt about what they might 
have passed on. One father, although he was not at all concerned about his 
own carrier state, said: ’I felt uncomfortable, I'd passed something on to my 
son‘. It was the same for one mother: ’You don't like to think you are going to 
pass anything awful to a child, I don't feel bad about it now but I did have this 
guilty feeling.’ 
4.6.4 Does disclosing CF carrier status alter parental behaviour towards 
the child? 
Parsons et al. (2003) did not invite parents to give their views on changed 
behaviour towards their child as a possible consequence of knowing their 
carrier status. Rather she gathered quantitative data to describe mother/baby 
relationships. Mothers all made reference to the fact that their baby was 
'perfectly healthy' and the way families talked about their baby's carrier status 
indicated that it caused them very little concern. She found no evidence that 
the mother/baby relationship had been affected by the carrier identification or 
that the carrier status was seen by parents as a problem in terms of ‘spoiled’ 
identity. 
Disclosing to parents newborn carrier status following routine blood spot 
screening 43 
 4.6.5 Does disclosing CF carrier status have implications for other family 
members? 
Parsons et al (2003) invited mothers to talk about how carrier identification 
had been discussed within their wider family. The majority of families talked at 
length about passing the news to other family members. The language 
however reflected feelings of ’obligation‘, with the use of phrases such as: ’it 
meant contacting‘, ’I had to pass information on‘, ’we felt we should‘, ’it's our 
responsibility to tell‘. In one family, discussions of carrier status had led to 
difficulties between grandparents. For another the brother, having been told, 
would not talk about it, and his carrier sister felt a distance not previously there 
had developed between them. Another couple felt they did not have enough 
information and were struggling to find the right words. Some parents found it 
difficult to understand why clinical geneticists were reluctant to test their other 
children. 
4.6.6 Is newborn screening acceptable to parents whose newborns are 
identified as carriers? 
Two studies addressed the acceptability of screening to parents in relation to 
the identification of carriers (Ciske et al., 2001; Parsons et al., 2003).  
Following newborn screening and genetic counselling, Ciske et al. (2001) 
reported that the majority of parents found it acceptable: they felt better 
informed and were glad to be aware of their child's CF carrier status,  they 
were not confused or experiencing feelings of guilt. Parsons et al. (2003) also 
reported that all the families who had their baby identified as a carrier were in 
favour of newborn screening. Typically, they favoured knowing the carrier 
status, and having the information available for when their children might start 
their own families. Typical comments were:  
’...glad I know... I would rather know than not know‘ (Parsons et al., 2003), p6. 
’...sooner things come to light the better... at least we know it's in the family 
now‘ (Parsons et al., 2003), p6. 
4.6.7 Are outcomes of disclosing carrier status influenced by the timing 
and content of pre-test and post-test information? 
In a CF programme employing an IRT test (Ciske et al., 2001), DNA test and 
sweat test, when asked how the newborn screening process should be 
improved, 55% of parents replied that they wished they had had more 
background information about the implications of the screening result earlier, 
before bringing their child for a sweat test. Although only 23% of parents 
suggested decreasing the waiting time to have a sweat test, the majority of 
parents indicated that the waiting was the worst part of the experience. The 
authors concluded that educational materials should be made available earlier 
and disseminated throughout community clinics. Ciske et al. (2001) concluded 
that educational programmes must be in place for both lay public and 
healthcare providers regarding the implications of newborn screening 
programmes.  
4.6.8 Are outcomes of disclosing carrier status influenced by which 
health professional provides parents with information? 
Parsons (2003) addressed the reporting of DNA analysis early in the 
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 screening pathway and the request for a sweat test. At this point in the 
pathway, screening results cannot distinguish carriers from affected children. 
Policy in Wales is for health visitors to be accompanied by a specialist CF 
nurse to request a second blood sample. In the study by Parsons et al. (2003), 
on four occasions two health professionals had called on the family to 
communicate results: the health visitor and a specialist CF nurse. For these 
families, this visit by a specialist to talk about CF just confirmed their worst 
fears. 
4.6.9 Are outcomes of disclosing carrier status influenced by parents’ 
previous knowledge of the screened conditions? 
None of the studies considered the significance of parents’ previous 
knowledge of the cystic fibrosis, and none of them considered parents’ 
awareness of either population risks, or their specific risks, of having the 
screened conditions.   
4.6.10 Are outcomes of disclosing carrier status influenced by the 
method of communicating carrier results? 
No studies have addressed the details of how to disclose confirmed carrier 
results. 
4.6.11 Are outcomes influenced by follow-up support?  
The Welsh study (Parsons et al., 2003), highlighted parents’ concern about 
being unable to ascertain the carrier status of their other children. They also 
highlighted the problems they faced in talking about carrier issues to other 
members of their family. 
4.6.12 What are the implications of an unclear diagnosis for cystic 
fibrosis? 
No studies addressed potential psychological implications arising from unclear 
diagnosis for cystic fibrosis.  
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 5. FINDINGS AND IMPLICATIONS 
Outline of Chapter 
This section summarises and discusses the main findings from each stage of 
this review – the mapping exercise and the in-depth review. 
 
This chapter should be read by practitioners, policy specialists and 
researchers wishing to implement interventions or design new interventions 
 
Key messages 
• This systematic review confirms the findings of a previous review of 
reviews (Stewart et al. 2003) in suggesting that, despite counselling, 
receiving a false positive screening result for cystic fibrosis can be 
difficult to understand and lead to anxiety, confusion and depression. 
Even after a normal sweat test some parents still worry about the 
health of their child. Although evidence from existing studies is weak, 
few parents appear to change their reproductive plans. 
• There is widespread parental acceptance of newborn screening 
despite short term difficulties; with raised IRT results appearing 
distressing.  
• There is very little research about parents’ responses to disclosing 
sickle cell  carrier results 
• There is no research about parents’ responses to the risk of CF in 
infants with one known CF mutation and a possible but unidentified 
mutation on the other allelle. 
 
5.1 Summary of principal findings  
5.1.1 Mapping exercise 
 
Extensive searching revealed 24 reports addressing the disclosure of carrier 
status to parents following newborn screening. None of the studies rigorously 
addressed the impact of that disclosure. Fifteen were intervention studies. 
Most of these addressed communication at the time of results disclosure (11) 
or later (9). Between them these were fairly evenly spread across the two 
conditions of interest and a broad spectrum of policy or practice that varied in 
terms of: the type of intervention (information/ education only, advice/ 
counselling or a combination); the intervention site (community/ primary care 
or secondary care); the health professionals involved (both specialists and 
non-specialists); and communication about the full range of possible test 
results. 
5.1.2 Nature of studies selected for in-depth review 
 
Ten of the intervention reports were from the USA, although the five from 
elsewhere (England and Wales) were more recent. 
However, none of these studies rigorously addressed the impact for parents of 
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 disclosing to them their newborn infant’s carrier status, or compared this with 
the impact of alternative tests (in the case of CF) that did not identify newborn 
carriers. Neither did any of them address the views of health professionals. 
The six studies eligible for in-depth review were not so evenly spread across 
the range of policy or practice options as the reports in the map. Only one 
addressed screening for sickle cell disorders. Between them, the remainder 
addressed communication about CF screening at the stages of requesting a 
second blood sample; reporting carrier status following early DNA and 
requesting a sweat test; and explaining false positives and disclosing carrier 
status after a sweat test. 
5.1.3 Synthesis of findings from studies in in-depth review 
Disclosing carrier status for sickle cell was addressed by only one study over 
twenty years ago in the USA, where parents of newborns were part of a larger 
study population. This notable lack of research literature suggests that sickle 
cell counselling services serve parents of newborn carriers on the basis of 
shared practitioner knowledge rather than formal research about parents’ 
views or evidence of impact. 
Five studies addressed universal screening for cystic fibrosis and were evenly 
split between information and education interventions and genetic counselling. 
Studies set in specialist clinics were more common than those in the 
community or primary care. We found no reports addressing the sensitive 
issue of non-paternity, despite this being regularly raised in policy and practice 
discussions convened by the UK Newborn Screening Programme Centre. 
Parents of newborn infants who are identified as CF carriers favoured 
newborn screening and knowing carrier status, and anticipated telling their 
child in due course. This was despite some parents experiencing the 
discovery of their own carrier status as another emotional event, albeit 
temporarily. In contrast, raised IRT test results began an emotionally 
disruptive experience for parents; this could also be difficult for the wider 
family who were simultaneously trying to be supportive. For some parents, 
false positive results could be a continuing cause for concern, while cystic 
fibrosis carrier status led to problems with insurance companies with some 
families in the USA. Taken together, learning of a raised IRT test results 
appears to be more of an emotional experience for parents than learning of a 
newborn’s carrier status. However, this conclusion is drawn from parents’ 
responses to unequivocal carrier status, with no apparent residual risk of the 
newborn having CF. 
A minority of parents used carrier status to inform reproductive planning, 
although when raised IRT results were withheld for four years as part of the 
Wisconsin trial parents felt misled and robbed of the opportunity to make 
decisions regarding reproduction. As antenatal screening becomes 
increasingly routine in the UK, more parents may use carrier information for 
reproductive planning. 
Our literature review suggests that few parents appeared to change their 
behaviour towards their carrier child, although evidence is weak. Discussing 
carrier status with the wider family was perceived as difficult, but necessary. 
There appears to be a need for follow-up information specifically to support 
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Our literature review suggests that parents would like some forewarning of 
possible results, but not to have ‘too much’ information. Parents favoured 
having familiar, non-specialists report test results to them; with these non-
specialists being sufficiently briefed and not alarmist. The presence of cystic 
fibrosis specialists to discuss raised IRT test results alarmed parents; as did 
being given information about cystic fibrosis at that stage. There is clearly a 
sensitive balance to be found between informing parents and worrying them 
unduly; and a need to provide non-specialists with sufficient information and 
skills to perform well in a situation they may rarely, if ever, encounter. 
There is little or no evidence about how outcomes are influenced by: parents’ 
previous knowledge of the screened conditions; the methods of 
communicating test results; or follow-up support. There is no reliable evidence 
about the implications for parents of an unclear diagnosis for cystic fibrosis. 
5.2 Strengths and limitations of this systematic review 
 
This is the first systematic review specifically about disclosing carrier status to 
parents following newborn screening. As such it provides valuable evidence of 
parents’ views to inform policy and practice. Previous systematic reviews have 
focused mainly on the efficacy of screening rather than communication about 
screening (Murray et al., 1999); (Pollitt et al., 1997). Although these earlier 
reviews did report some studies about disclosing carrier status ,(Baroni et al., 
1997; Farrell et al., 2001; Laird et al., 1996; Rao et al., 1996; 1991; Tluczek et 
al., 1992), the current review also reviewed in-depth five other studies (Ciske 
et al., 2001; Moran and Quirk, 2002; Parsons et al., 2003; Wheeler et al., 
2001; Whitten et al., 1981). The current review also included relevant studies 
not included in a systematic review of psychosocial aspects of genetic 
screening (Green et al., 2004). 
Although inclusion of more studies is a strength of this review, the studies 
included are weak in terms of the number and selection of participants and 
reporting of socio-demographic data. Evidence about parents’ views of their 
children’s sickle cell status was drawn from 113 parents (Whitten et al. 1981). 
Evidence about disclosing raised IRT results was drawn from 242 Americans 
with an education level higher than average (Ciske et al., 2001; Tluczek et al., 
1991) and 31 parents from the UK for whom there is no reported socio-
demographic data (Moran and Quirk, 2002; Parsons et al., 2003). Evidence 
about parents’ views of disclosing newborn CF carrier status is from 138 US 
families, with a higher than average education (Ciske et al., 2001) and 10 
parents in Wales, for which no socio-demographic data is reported (Parsons et 
al., 2003). 
 
As with all secondary research, it is possible that this review has been unable 
to identify other relevant literature and it is not possible to gauge the impact 
that absence of this literature may have had. Though the searches were as 
extensive as possible, there was no extensive search of grey literature. This 
may be a particularly rich source of practice knowledge about counselling 
following sickle cell carrier results; an area that is poorly represented in the 
literature identified by this review. Other sources of evidence may be non-
English language databases in addition to LILACS, searched for this review. 
Disclosing to parents newborn carrier status following routine blood spot 
screening 48 
 5.3 Other literature 
The current review confirms the suggestions from previous reviews (Stewart 
and Oliver, 2003) that, despite counselling, receiving a false-positive 
screening result for cystic fibrosis can be difficult to understand and lead to 
anxiety, confusion and depression. Even after a normal sweat test some 
parents still worry about the health of their child. Few parents appeared to 
change their reproductive plans. 
The current review adds to previous knowledge by documenting widespread 
parental acceptance of newborn screening despite largely temporary 
difficulties experienced with raised IRT test results and disclosure of newborn 
carrier status; the former appearing more traumatic than the latter. It also 
provides evidence of parents’ preference for well-briefed non-specialists 
reporting raised IRT test result or carrier status, and the difficulties parents 
experience when discussing screening results with their wider family. This 
supports the findings of a similar study about parental responses to repeat 
testing of infants with ‘false positive’ results when screening for other 
conditions within a blood spot programme. Sorenson et al. (1984) reported 
that parents who were aware that the initial test was abnormal were no more 
anxious or depressed than other parents while waiting for repeat test results. 
Over one-third of parents of these normal infants subsequently expressed 
concern about the health of their infant because of the repeat testing. This 
concern was not related to a parent’s knowledge that the initial test result was 
abnormal, but was greater in parents reporting that they had not received 
sufficient information about the screening process and its significance for the 
health of their infant. 
The review reported here has revealed a lack of evidence about the impact of 
disclosing carrier status to parents following newborn screening. In addition, 
conclusions about parents’ positive views about disclosing carrier status need 
to be interpreted with caution for three reasons. First, the relative low numbers 
involved, the poor reporting of socio-demographic data in some studies, and 
the biased inclusion of better educated parents in other studies, precludes 
generalising the findings to wider populations. Second, none of the relevant 
studies addressed the possibility of carriers of a single identified mutation 
being at risk of having CF. Third, it is possible that more literature is available 
in languages other than English, especially about screening for sickle cell 
disorders.  
We did not review in depth studies that did not address parents’ views. These 
included an American survey of screening programmes (Farrell et al., 2001); 
an economic evaluation (1998); and an assessment of needs for educational 
provision about haemoglobinopathies for midwives in England (1996). Each of 
these studies has been followed-up in different ways elsewhere. The 
American survey informed a survey of cystic fibrosis screening services in the 
UK undertaken in parallel with the current review (Lempert et al., 2004). The 
economic evaluation has been reviewed by the Centre for Reviews and 
Dissemination (http://www.york.ac.uk/inst/crd/). The needs assessment has 
been followed by the commissioning of a training programme for sickle cell 
and thalassaemia screening in England and Wales (http://www-
phm.umds.ac.uk/haemscreening/). 
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 5.3 Implications 
Implications for policy must be cautious, considering the low numbers and 
selective nature of the study populations. 
5.3.1 Policy 
The findings of this review provide some support for a policy decision to 
include DNA testing early in the screening protocol in order to reduce the 
numbers of parents experiencing excessive anxiety between hearing of a 
positive screening result (raised IRT test) and a confirmed result. However this 
is based on specialist outreach models of care; little is known about how to 
support non-specialists in this work. There is no support for not disclosing 
newborn carrier status or raised IRT test results to parents. 
Little is known about the views of parents with less formal education. 
Other parents prefer positive screening results or requests for repeat tests to 
be communicated by a familiar, non-specialist community/ primary care 
practitioner. Investment is needed in materials and training to support these 
health professionals to undertake well a task they may rarely, if ever, 
encounter. There is a particular need for interventions to support parents who 
wish to discuss screening results with their wider family. 
Parents, other family members and practitioners should be involved in 
developing these interventions.  
5.3.2 Practice 
Individual practitioners have a responsibility to forewarn parents about the 
possibility of positive screening results or requests for repeat tests and, when 
they occur, to discuss these with parents themselves rather than referring 
them to specialist services prematurely. 
5.3.3 Research 
With a dearth of published research findings about disclosing sickle cell carrier 
status, we recommend seeking grey literature through practitioner networks. 
We found no research addressing the issue of disclosing non-paternity 
through identification of carrier status in newborn screening. This should be 
addressed with primary research. 
Research is particularly needed about the implications for parents of an 
unclear diagnosis for cystic fibrosis and how to provide appropriate follow-up 
care. 
More particularly needs to be known about the views and experiences of 
parents with less formal education. 
Some parents would like to be offered cascade carrier testing for other 
children. As this contradicts current guidelines, we recommend research to 
explore the views of parents and children, and the possible implications. 
Parents, other family members and practitioners should be involved in guiding 
this research. 
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 APPENDICES 
 
APPENDIX 2.2: Search strategy for electronic databases 
 
Strategy created for MEDLINE (OVID online) and adapted for other 
databases. 
1 – 17: Newborn Screening and Blood Spot Test 
 
1     exp neonatal screening/ (2232) 
2     exp "sensitivity and specificity"/ (120680) 
3     specificity.ti,ab,kw. (148030) 
4     false negative.mp. (10791) 
5     false positive.mp. (17255) 
6     ((infant or newborn or baby or neonat$ or perinat$) adj3 
screen$).ti,ab,kw. (3469) 
7     exp predictive value of tests/ (42877) 
8     exp ROC curve/ (5247) 
9     exp diagnosis/ (2913675) 
10     mass screening/ (39096) 
11     exp blood specimen collection/ (7770) 
12     exp fetal blood/ (16439) 
13     (heel adj3 prick).ti,ab,kw. (83) 
14     heel/ (1339) 
15     guthrie.ti,ab,kw. (351) 
16     (screen$ adj3 card).ti,ab,kw. (54) 
17     "blood spot".ti,ab,kw. (345) 
 
18     or/1-17 (3055534) 
 
19 – 47: Screening / Diagnostic Tests and Results 
 
19     heterozygote/ (20976) 
20     exp heterozygote detection/ (5582) 
21     carrier state/ (12401) 
22     carrier.ti,ab,kw. (35185) 
23     trypsin/ (31003) 
24     trypsinogen/ (1165) 
25     (sweat adj3 test).ti,ab,kw. (386) 
26     skin temperature/ (6277) 
27     cystic fibrosis/ (16711) 
28     (immunoreactive adj3 trypsin$).ti,ab,kw. (415) 
29     irt.ti,ab,kw. (432) 
30     exp hemoglobinopathies/ (22375) 
31     exp electrophoresis/ (249400) 
32     hemoglobin electrophoresis.ti,ab,kw. (208) 
33     haemoglobin electrophoresis.ti,ab,kw. (84) 
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 34     hypertrypsin?emic.mp. (2) 
35     sickle cell.mp. (8773) 
36     exp anemia, sickle cell/ (10591) 
37     hemoglobin sc disease/ (404) 
38     sickle cell trait/ (1280) 
39     exp hemoglobin c disease/ (389) 
40     ((haemoglobin or hemoglobin) adj2 (d or e or o)).mp. (978) 
41     "haemoglobin a".ti,ab,kw. (11392) 
42     "hemoglobin a".ti,ab,kw. (32038) 
43     "haemoglobin as".ti,ab,kw. (13359) 
44     "hemoglobin as".ti,ab,kw. (38920) 
45     hereditary persistence of fetal haemoglobin.mp. (58) 
46     hereditary persistence of fetal hemoglobin.mp. (233) 
47     hpfh.mp. (274) 
 
48     or/19-47 (424345) 
 
49 – 59: Disclosure of Results 
 
49     disclos$.mp. (29726) 
50     exp disclosure/ (11850) 
51     non-disclosure.ti,ab,kw. (33) 
52     "non disclosure".ti,ab,kw. (33) 
53     exp truth disclosure/ (7074) 
54     exp confidentiality/ (12749) 
55     exp communication/ (162227) 
56     exp duty to warn/ (976) 
57     ((disclos$ or communicat$ or break$ or deliver$ or tell$) adj3 (bad 
news or result$ or test$ or state or status or diagnosis)).ti,ab,kw. 
(14936) 
58     ((disclos$ or communicat$ or break$ or deliver$ or tell$) adj3 
(parent$ or patient$ or famil$ or guardian$ or mother or 
father)).ti,ab,kw. (21115) 
59     ((patient or user or parent or consumer or mother or father) adj3 
(informat$ or leaflet$ or pamphlet$ or letter$ or telephone or 
phone)).ti,ab,kw. (9110) 
 
60     or/49-59 (229216) 
 
61 – 109: Possible Outcomes and Factors of Screening / Disclosure 
 
61     ((psychosocial or psychological or emotion$ or social or educat$ 
or famil$) adj3 (impact$ or factor$ or effect$ or outcome$ or implicat$ or 
state or status)).ti,ab,kw. (71765) 
62     Stress, Psychological/et [Etiology] (3077) 
63     anxiety/et (2250) 
64     exp paternity/ (1873) 
65     ((non or false) adj3 paternity).ti,ab,kw. (93) 
66     biological father.ti,kw,ab. (69) 
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 67     reproduction/ (18896) 
68     ((reproduct$ or pregnan$) adj3 (choice$ or plan$ or future$ or 
issue$ or implicat$ or behavio$ or decision$)).ti,ab,kw. (7345) 
69     parents/ (18576) 
70     exp parent-child relations/ (26225) 
71     exp family relations/ (35377) 
72     exp false positive reactions/ (15150) 
73     exp false negative reactions/ (10612) 
74     professional family relations/ (5916) 
75     physician patient relations/ (33285) 
76     nurse patient relations/ (16848) 
77     ethics/ (8069) 
78     exp principle-based ethics/ (9813) 
79     patient education/ (33279) 
80     language/ (10133) 
81     translat$.mp. (74513) 
82     exp patient acceptance of healthcare/ (59956) 
83     genetic privacy/ (532) 
84     genetic counseling/ (7811) 
85     (referal or refer or consult$).ti,ab,kw. (36913) 
86     exp patient care management/ (225785) 
87     exp "health care quality access and evaluation"/ (2237642) 
88     (insurance or employment or education or pension$ or 
morgage).mp. (159776) 
89     "social$ exclus$".mp. (60) 
90     carrier.ti,ab,kw. (35185) 
91     heterozygote detection/ (5582) 
92     awareness/ (4463) 
93     risk/ (64162) 
94     family health/ (8093) 
95     midwife.ti,ab,kw. (1802) 
96     informed consent/ (18411) 
97     patient advocacy/ (16846) 
98     (informed adj3 (choice or decision)).ti,ab,kw. (883) 
99     time factors/ (577731) 
100     "lifetime health".kw,ti,ab. (40) 
101     knowledge attitudes practice/ (17826) 
102     attitude of health personnel/ (40350) 
103     "Referral and Consultation"/ (28568) 
104     carrier state/ (12401) 
105     counsel$.ti,ab,kw. (26648) 
106     exp community health services/ (274882) 
107     heterozygote/ (20976) 
108     social support/ (17896) 
109     ((patient or user or parent or consumer or mother or father) adj3 
(informat$ or leaflet$ or pamphlet$ or letter$ or telephone or 
phone)).ti,kw,ab. (9110) 
110     or/61-109 (3160825) 
111     and/18,48,60,110 (630) 
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 APPENDIX 4.1: Details of studies included in in-depth review  
Screening Programme 
Author 
Country Condition and setting 
of communication 
Population 
Study design and data collection 
Ciske, D.J. 
et al (2001) 
USA  
Wisconsin 
CF: specialist clinic  Parents of 138 families: educational background 
diverse, but better educated than comparable 
population of Wisconsin young adults  
Post-test only outcome evaluation: 
one to one interview (face to face or 
by phone) and self-completion 
questionnaire  
Moran, J. et 
al (2003) 
UK  
England 
CF: home  21 Parents; no socio-demographic data, only 36 of 
168 eligible families ‘contactable’ 
Cross-sectional survey - qualitative 
study: One to one interview (face to 
face or by phone) 
Parsons, 
E.P. et al 
(2003) 
Wales CF: home and specialist 
clinic  
10 parents of carrier babies; 82 mothers from general 
population. No socio-demographic data 
Case control study: One to one 
interview (face to face or by phone) 
Tluczek, A. 
et al (1991) 
USA  CF: specialist CF centre; 
home by telephone 
 
Parents of 104 infants with false positive IRT test 
results: 78% white; 64% married; 40% of mothers 
and 43% of fathers had education beyond high 
school. 
Outcome evaluation: One to one 
interview (face to face or by phone) 
and self-completion questionnaire  
 
Wheeler, 
P.G. et al 
(2001) 
USA  
Massachusetts 
CF: specialist clinic in  
academic centre 
Parents of 95 families; no socio-demographic data Case series: no methods reported 
Whitten, 
C.F. et al 
(1981)  
USA  Sickle cell disorders: 
community site - a mobile 
unit in a variety of 
settings: schools, 
churches, supermarkets, 
at public meetings and 
the State Fair. 
192 adults/ parents 
Counsellees were adults who were sickle cell carriers 
or were parents of a child who was a sickle cell 
carrier. 153 women, 62 married, 97 under 30, 34 of 
the respondents had no children, 110 had between 1 
and 3 children and 36 had more than 3; In 79 
instances the counsellee had sickle cell trait, in 80 
the child did, and in 33 both the counsellee and their 
child were carriers. 
outcome evaluation - post test only: 
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 APPENDIX 4.2: Details of interventions included in in-depth review 
Author Type of intervention  Health professional communicating 
Timing of the 
communication 
Ciske, D.J. et al 
(2001) 
Advice/counselling  
Immediately after the sweat test that revealed the child did not have CF, and 
therefore the screening result was 'false positive', a communication session 
occurred with the parents that included a description of the sweat chloride result 
and its interpretation, information about the genetics of CF, an offer to arrange 
additional CFTR analysis in parents and family members, and information about 
the implications of CF heterozygote status for further reproduction. 
specified 
genetic counsellors; nurse 
practitioners; physician 
at time of heel-
prick test 
 
result disclosure 
Moran, J. et al 
(2002) 
Advice/counselling  
 
Information/education  
CF nurse and HV visited parents at home after raised IRT to explain the need for 
a further test - providing information and counselling. Blood test taken and results 
provided within one to two weeks. Family informed as soon as possible by 
telephone if result normal. Copies of letter to GP, HV and parents. 
specified 
health visitor; CF nurse 
at time of 
subsequent test 
requesting second 
blood sample 
result disclosure 
Parsons, E.P. et al 
(2003) 
Information/education  specified 
Health visitor and GP to 
inform them about sweat 
testing. 
 
Paediatrician, specialist 
CF nurse and health 
visitor to arrange the date 
for the sweat test. 
 
Paediatrician for giving 
results of sweat test on 
the same day. 
result disclosure 
Tluczek, A. et al 
(1991) 
Information/education  
the intervention was disclosing results to parents 
specified 
physician (sweat test); CF 
centre physician 
result disclosure 
at un-blinding 
when baby 4 yrs 
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Wheeler, P.G. et 
al (2001) 
Advice/counselling  specified 
genetic 
counsellor 
at time of subsequent test 
Results of DNA testing and the 
implications were discussed 
prior to giving the results of the 
sweat test. 
post-result disclosure 
24 hours after sweat test 
Whitten, C.F. et 
al (1981)  
Advice/counselling  
Counselling sessions about carrier status were recorded and analysed in terms of 
counsellors' performance and counsellee's response to carrier status. 
specified 
sickle cell 
counsellors 
post-result disclosure 
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 APPENDIX 5: Glossary 
 
All terms in bold are included within the glossary 
 
 
 
affected When someone has a condition, it is said that they are affected. A child 
who is affected with cystic fibrosis, is a child who has cystic fibrosis.
 
 
antenatal screening Antenatal screening, is screening which is carried out before a baby is 
born. This can include doing tests on the pregnant mother, her partner 
or the unborn baby. Antenatal screening includes tests for a wide 
range of conditions. 
 
 
audit A systematic monitoring of screening and treatment procedures. 
blood sampling This refers to the collecting of small amounts of blood. In the case of 
newborn screening it refers to the collection of small amounts of blood 
from the baby's heel when they are about a week old. This is done by 
pricking the heel. 
 
 
blood spot When newborn babies are about a week old a sample of blood is taken 
from their heel. The blood spot is stored on a special type of filter 
paper, called a Guthrie card. A number of tests are then carried out on 
this blood spot. These tests are often called newborn blood spot 
screening.  
 
 
carrier An individual who carriers a single gene for a condition where two 
genes are required for an individual to be affected. The carrier can 
pass on the gene to their offspring who may be affected if they also 
inherit another gene from their other parent. A carrier is a heterozygote 
for the gene carried. 
 
 
case An individual with a health condition. 
 
 
Child Health 
Department (often 
referred to as 'child 
health') 
The Child Health Department monitors each child who is born. When a 
mother gives birth the Child Health Department is notified of the birth. 
The results of newborn screening tests are also reported to Child 
Health. 
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 Child Health Record 
(also called PCHR) 
Personal Child Health Record - this is the child health record which is 
held by the parent. It is normally issued by the health visitor. 
 
 
clinical standards Agreed standards that should be attained by health professionals in 
caring for individuals. 
 
 
condition There are lots of different word used to describe illnesses. They are 
sometimes called diseases, or disorders, or conditions. 
 
 
congenital hypothyroidism 
(CHT) 
Congenital hypothyroidism - a condition which is tested for in 
newborn babies. People with congenital hypothyroidism don't produce 
thyroid hormones properly. This can affect the development of the 
baby's organs, in particular the brain. If identified early the baby can be 
treated and can lead a healthy life. CHT has been screened for 
throughout the UK since the 1980s. 
 
 
confirmed result A confirmed result is one which has been confirmed. The results of 
initial screening tests are not usually 100% certain, and are often 
called presumptive results. The results of screening tests are NOT 
confirmed results. They are often confirmed later, with further tests. 
 
 
consent Agreement to a plan of action or particular treatment. 
 
 
coverage When talking about screening programmes, people often talk about 
coverage. This is the number of people actually screened. For example 
there are sometimes concerns that coverage is poor amongst families 
from particular backgrounds, or religions. The success of screening 
programmes is sometimes measured by the coverage achieved. 
 
 
cystic fibrosis Cystic fibrosis - this is a condition which affects the organs in the body, 
especially the lungs and pancreas, by clogging them with thick sticky 
mucus. New treatments mean people with cystic fibrosis can live 
relatively healthy lives. Their standard of life is improved if the condition 
is detected and treated in the first months of life. Cystic fibrosis is more 
common in some populations within the UK than others. Some areas 
have been screening for CF in the UK since the 1980's. Within the next 
few years all newborn babies will be screened for cystic fibrosis. 
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 diagnosis / diagnostic test A diagnostic test is one which tests for a specific condition, and 
allows doctors to make a diagnosis, confirming whether or not 
someone has a condition. Diagnostic tests often follow screening tests. 
For example a newborn baby might be screened for cystic fibrosis. 
The screening result is that the baby probably has the condition. Further 
diagnostic tests will then be carried out to find out whether the child 
definitely has cystic fibrosis. This is then considered the confirmed 
result. 
 
 
disease There are lots of different words used to describe illnesses. They are 
sometimes called diseases, or disorders, or conditions. 
 
 
disorder There are lots of different words used to describe illnesses. They are 
sometimes called diseases, or disorders, or conditions. 
 
 
false-negative A false-negative result is one which is thought to be negative, but this 
turns out to be false. Children who have a false-negative results for 
PKU are those who are told that they don't have the condition, and then 
it turns out that they do have PKU. Depending on the condition, this can 
be very serious. If a child is not treated quickly for PKU their brain will 
not develop properly. 
 
 
false-positive A false-positive result, is one where the result is thought to be positive, 
but this turns out to be false. A child who has a false-positive result for 
PKU, is a child who has been told they have the condition, and then it 
turns out that this is not the case. For parents, receiving a false-positive 
result can mean that they think that their child is sick, when actually they 
are healthy. 
 
 
Guthrie Card When the midwife collects small drops of blood from a newborn baby, 
she puts them on a special piece of filter paper called a Guthrie Card. 
This special card allows the blood to be stored while it is sent to the 
laboratory for testing. 
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 haemoglobinopathies Haemoglobinopathies - disorders of the haemoglobin. Haemoglobin is 
the part of our blood which carries oxygen. There a large number of 
different haemoglobinopathies, some are more serious than others. 
Sickle cell disease is a haemoglobinopathy. Haemoglobinopathies are 
more common in some populations within the UK than others. 
Haemoglobinopathies can be tested for in pregnant mothers, and 
unborn babies, as well as newborn babies. Some areas have been 
screening newborn babies for haemoglobinopathies in newborn babies 
since the 1980s. In many areas only those babies thought to be at high 
risk are tested. This is changing and over the next few years all 
newborn babies will be screened for haemoglobinopathies. 
 
 
heel prick When a baby is about a week old, the midwife will prick the baby's heel 
and collect some small drops of blood. This blood is then used for 
screening. 
 
 
heterozygote A heterozygote carries two different versions of the same gene. Where 
the health condition requires two versions of the same gene the 
heterozygote is a carrier. 
 
 
informatics Health informatics is an evolving scientific discipline that deals with the 
responsible collection, storage, retrieval, communication and optimal 
use of health related data, information and knowledge. to improve 
patient care, medical education, and health sciences research. 
 
 
National Screening 
Committee 
The UK National Screening Committee - this is a national advisory 
body which makes recommendations about screening to the 
Department of Health. 
 
 
negative result A negative result is a result which shows that the child does not have 
(or is unlikely to have) the condition which is tested for. Sometimes 
people will say that the result is normal. 
 
 
neonatal screening Neonatal screening can also be called newborn screening. All 
screening on a newborn baby is called newborn (or neonatal) 
screening. There are different newborn screening tests, for example 
includes hearing screening, hips screening and blood spot screening.  
 
 
normal (result) Sometimes when the result of the test shows that the child does not 
have (or is unlikely to have) the condition tested for, people say the 
result is normal. In general it is best to avoid using this term, as it is not 
always clear what normal is meant to be. Its meaning may be unclear 
to both parents and health professionals. 
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 notification When talking about screening people often refer to notification of 
results. This can mean a number of slightly different things. Sometimes 
notification means the reporting of a screening result to a register, or a 
health monitoring group, such as the child health record. Sometimes 
notification refers to telling parents or patients the results of their tests. 
When talking about notification, it is important to be clear about what 
information is being notified, and who is being notified about this 
information. 
 
 
Parent Support 
Research Team 
The Parent Support Research Team is part of the UK Newborn 
Screening Programme Centre. It is based at the Institute of Education, 
University of London. It is their responsibility to support parents involved 
in the Programme Centre's work. Working with parents and health 
professionals, it will be designing parent information about newborn 
screening, and communication guidelines and training for health 
professionals. 
 
 
PHCR (Also called the 
Child Health Record) 
Personal Child Health Record - this is the child health record which is 
held by the parent. It is normally issued by the health visitor. 
 
 
phenylketonuria (PKU) Phenylketonuria - a condition which is tested for in newborn babies.  It 
affects how protein is broken down in the body. If untreated this leads to 
poor brain development. If it identified early then the child can be put on 
a special diet and the brain can develop normally. PKU has been 
screened for throughout the UK since 1969. 
 
positive result A positive result is a result which shows that the child does have (or is 
likely to have) the condition which is tested for. Sometimes people will 
say that the child is affected. 
 
 
presumptive results Presumptive results are results which are not yet confirmed, but which 
are considered highly likely. A presumptive positive for PKU means that 
is very likely, or assumed that the child has PKU. This result is then 
confirmed using a diagnostic test. Screening results are described as 
presumptive. A presumptive positive can also be described as a screen 
positive. A presumptive negative can also be described as a screen 
negative. 
 
process standards Agreed standards that should be achieved at each stage of the 
screening process: informing parents, taking the sample, laboratory 
testing, informing clinicians and parents of the results, starting treatment 
of affected newborns as soon as it is beneficial. 
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 quality assurance A system for monitoring and maintaining high standards in every aspect 
of the screening programme. 
 
 
registers / disease registers There are a number of disease registers in the UK which keep a 
record of the number of people with particular conditions. These 
registers can serve different purposes: ensuring people with the 
condition are followed up, and treated and helping us to understand 
more about these conditions and how they effect people etc. There are 
different registers which collect slightly different information about 
different conditions. One of the tasks of the Programme Centre is to 
develop and maintain national registers for conditions which are 
screened for in newborn blood spot screening. 
screen negative 
(results) 
Screening results are not 100% conclusive. Instead they provide 
presumptive results, which are then confirmed using diagnostic 
tests. A screen negative result for CF means that it is highly likely that 
the child does NOT have CF. This screen negative result is NOT usually 
confirmed using further tests, but it is assumed the child is not affected.
 
 
screen positive (results) Screening results are not 100% conclusive. Instead they provide 
presumptive results, which are then confirmed using diagnostic 
tests. A screen positive result for CHT means that it is highly likely that 
the child has CHT, but that this must still be confirmed by further tests. 
 
 
screening Screening is when healthy children and adults are tested to see if they 
are likely to develop a condition. Screening tests don't generally confirm 
that people have a disease. Usually they will not feel ill from these 
conditions in any way at the time when they're screened. Screening 
allows diseases to be identified early, before any signs of illness. This 
means people can be treated quickly, and hopefully avoid getting 
seriously ill. Screening can happen at different stages, and for different 
conditions. Newborn screening in this country includes tests for 
phenylketonuria (PKU), congenital hypothyroidism (CHT), cystic 
fibrosis (CF), and haemoglobinopathies. 
 
 
Screening protocol A screening protocol lists the procedures and tests for collecting and 
testing a sample when screening for a health condition. 
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 sensitivity When discussing how good a particular test is, people talk about 
sensitivity. Sensitivity is a way of measuring how sensitive a test is to 
the condition; how good it is at finding the condition. When a test is 
very sensitive it will pick up all the cases of the disease. When a test is 
not very sensitive is will miss some of the cases. This means that 
screening test which is not very sensitive will show that some people do 
not have the condition, when actually they do but the test wasn't 
sensitive enough to pick them up. When people are told that they do not 
have a condition, but really they do, this is called a false-negative 
result. Tests that are not very sensitive produce more false-negative 
results. 
 
 
setting standards The process by which minimum acceptable standards, achievable 
standards and optimal standards are agreed. This is usually through 
discussion and review of current practice and research. 
 
 
sickle cell disorders Sickle Cell disorders are conditions which affect the way that our 
blood carries oxygen. The part of the blood which carries oxygen is 
called haemoglobin, which is found inside our red blood cells. Sickle 
Cell disorders can also be called haemoglobinopathies. The name 
sickle cell disease, is also used, usually used to describe one 
particular type of sickle cell disorder. A person who has sickle cell 
disease has some red blood cells which are shaped like sickles. These 
cells cannot carry oxygen properly. The condition can be very painful 
and can cause various health problems. 
 
 
specificity When discussing how good a particular test is, people talk about 
specificity. Specificity is a way of measuring how good a test is at 
picking up only the people who have the condition. A test with poor 
specificity is one which isn't very specific, and identifies people with 
disease, but also some other people who don't have the disease.  A 
screening test which is not very specific will have some results which 
show a person has an illness, when actually they don't. This kind of 
result is called a false-positive result. Tests which are not very specific 
produce more false-positive results. 
 
 
true-negative A true-negative result is one which is thought to be negative, and this is 
true. A person with a true negative result for a CHT, is someone who 
does not have CHT. 
 
 
true-positive A true-positive result is one which is thought to be positive, and this is 
true. A person with a true positive result for a condition, is someone who 
has that condition. 
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 UK The UK includes England, Wales, Scotland and Northern Ireland. 
 
 
UK Newborn Screening 
Programme Centre 
The UK Newborn Screening Programme Centre has been funded by 
the Department of Health to develop national standards for newborn 
blood spot screening. The Programme Centre is made up of a team of 
people from Great Ormond Street Hospital for Children, the Institute of 
Child Health and the Institute of Education. 
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